WO2017148406A1 - 嘧啶类七元环化合物、其制备方法、药用组合物及其应用 - Google Patents
嘧啶类七元环化合物、其制备方法、药用组合物及其应用 Download PDFInfo
- Publication number
- WO2017148406A1 WO2017148406A1 PCT/CN2017/075416 CN2017075416W WO2017148406A1 WO 2017148406 A1 WO2017148406 A1 WO 2017148406A1 CN 2017075416 W CN2017075416 W CN 2017075416W WO 2017148406 A1 WO2017148406 A1 WO 2017148406A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- piperazinyl
- amino
- piperidinyl
- cyano
- nitro
- Prior art date
Links
- 0 *N(c1c2cccc1)c(nc(NC1=CI=CC=C1)nc1)c1N(*)C2=O Chemical compound *N(c1c2cccc1)c(nc(NC1=CI=CC=C1)nc1)c1N(*)C2=O 0.000 description 5
- INUSQTPGSHFGHM-UHFFFAOYSA-N [O-][N+](c(c(Cl)n1)cnc1Cl)=O Chemical compound [O-][N+](c(c(Cl)n1)cnc1Cl)=O INUSQTPGSHFGHM-UHFFFAOYSA-N 0.000 description 2
- QEVYSBDKFUBZPU-UHFFFAOYSA-N CN(c(cccc1)c1C(OC)=O)c1nc(Cl)ncc1[N+]([O-])=O Chemical compound CN(c(cccc1)c1C(OC)=O)c1nc(Cl)ncc1[N+]([O-])=O QEVYSBDKFUBZPU-UHFFFAOYSA-N 0.000 description 1
- UWJSLZSYXDIOTD-UHFFFAOYSA-N CN(c1c(N(CC2)c3c2cccc32)nc(Nc(cc3)ccc3NS(C)(=O)=O)nc1)C2=O Chemical compound CN(c1c(N(CC2)c3c2cccc32)nc(Nc(cc3)ccc3NS(C)(=O)=O)nc1)C2=O UWJSLZSYXDIOTD-UHFFFAOYSA-N 0.000 description 1
- DXGQKECDXIUGEE-UHFFFAOYSA-N CN(c1c(N(CC2)c3c2cccc32)nc(Nc(cc3)ccc3S(N)(=O)=O)nc1)C2=O Chemical compound CN(c1c(N(CC2)c3c2cccc32)nc(Nc(cc3)ccc3S(N)(=O)=O)nc1)C2=O DXGQKECDXIUGEE-UHFFFAOYSA-N 0.000 description 1
- YQCGWRUPVKYKRY-UHFFFAOYSA-N CN(c1c(N(CC2)c3c2cccc32)nc(Nc3cccc(S(N)(=O)=O)c3)nc1)C2=O Chemical compound CN(c1c(N(CC2)c3c2cccc32)nc(Nc3cccc(S(N)(=O)=O)c3)nc1)C2=O YQCGWRUPVKYKRY-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
Definitions
- the present invention relates to the field of medicinal chemistry, and in particular to a compound having a compound which inhibits Mst 1/2 protein kinase activity, a preparation method thereof, a pharmaceutical composition comprising the same, and a pharmaceutical composition comprising the same and a pharmaceutical composition comprising the same It is used for promoting regeneration and repair of tissues and organs, promoting stem cell proliferation and dedifferentiation of adult cells, immunosuppression, prevention or treatment of diseases associated with diseases and diseases of ischemia in vivo.
- Protein kinases play a key role in cell signaling through phosphorylation of substrates, involving almost every aspect of cellular physiology (Science, 2002, 298, p1912–1934). Disorders of kinase overexpression and function are closely related to diseases such as cancer, metabolic diseases, neurodegenerative diseases and inflammation.
- the first Bcr-Abl kinase inhibitor Gleevec against chronic myeloid leukemia The successful launch of the era opens the era of targeted anti-tumor drugs (Nat. Rev. Cancer, 2009, 9, p28-39).
- kinases have become the second largest drug target of pharmaceutical companies for new drug development, and 32 small molecule kinase inhibitors have been approved by the US FDA for clinical treatment.
- Hippo signaling pathway plays an important role in regulating the differentiation and proliferation of tissue-derived stem cells, regulating organ size and maintaining tissue homeostasis (Cell Biosci., 2013, 3, p34; Nat Cell Biol. 2011, 13(8): p877 -83.).
- Conditional knockout of the key molecule Mst1/2 protein kinase in the Hippo signaling pathway promotes liver regeneration (Cancer Cell, 2009, 16, p425-438), which plays an immunosuppressive role (J. Exp. Med. 2012, 209 , p741-759).
- Decreasing the protein level or kinase activity of the kinase Mst1/2 will help reduce neuronal cell death and thus be useful in the prevention and treatment of neurological disorders or neurodegenerative diseases, including Alzheimer's disease, multiple sclerosis, Parkinson's disease, Cerebral stroke (Cell 2006, 125, p987-1001); and oxidative stress-related myocardial ischemia and peripheral ischemic disease (US 2008/0242608).
- the inventors of the present invention have designed and synthesized a series of polysubstituted pyrimidines having a novel structure, high safety and high activity against Mst 1/2 kinase. Metacyclic derivatives, and the activity of this novel derivative to promote tissue regeneration and repair has been studied.
- the present invention provides a compound of the formula:
- Another object of the present invention is to provide a process for the preparation of the above compounds.
- Another object of the present invention is to provide a pharmaceutical composition comprising the above compound.
- Another object of the present invention is to provide a pharmaceutical composition comprising the above compound and a pharmaceutical composition comprising the same in the preparation for promoting regeneration and repair of tissues and organs, promoting stem cell proliferation and adult cell dedifferentiation, immunosuppression, prevention or treatment.
- a pharmaceutical composition comprising the above compound and a pharmaceutical composition comprising the same in the preparation for promoting regeneration and repair of tissues and organs, promoting stem cell proliferation and adult cell dedifferentiation, immunosuppression, prevention or treatment.
- Figure 1 is a schematic diagram showing the measurement of the activity of the enzyme-linked immunosorbent kinase Mst 1/2.
- Figure 2 illustrates that Compound II-1 is effective in promoting liver regeneration from partial hepatectomy.
- the mice were injected twice a day with Compound II-1 (1 mg/kg body weight) or the control solvent, a) the ratio of liver to body weight; b) Ki67-positive proliferating hepatocytes in liver tissue sections The percentage in .
- Student's t-test was compared between the drug-treated group and the control group, *P ⁇ 0.05, ***P ⁇ 0.001.
- Figure 3 illustrates that Compound II-1 is effective in promoting intestinal repair in a DSS-induced intestinal injury model.
- DSS-fed (1-7 days) mice were injected intraperitoneally with compound II-1 (1 mg/kg body weight) or control solvent, a) percentage change in body weight; b) daily DAI value record; c) experimental group and Immunohistochemical staining of Yap, BrdU and Ki67 in intestinal tissues of control mice; d) and e) Percentage of BrdU and Ki67 positive cells in intestinal tissues of experimental and control mice. Student’s t-test was compared between the drug treatment experimental group and the control group, *P ⁇ 0.05, ***P ⁇ 0.001.
- the present invention has been achieved by the following technical solutions.
- the invention provides a compound represented by the following formula:
- R 1 is selected from:
- C1-C6 alkyl optionally substituted by halogen, nitro, cyano; C1-C6 oxyalkyl; C3-C7 cycloalkyl, optionally substituted by halogen, nitro, cyano ; -O-C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; -O-C3-C7 cycloalkyl, optionally halogen, nitro, amino, cyano Substituted; C6-C10 aryl, optionally substituted by halogen, nitro, amino, cyano; -O-C6-C10 aryl, optionally substituted by halogen, nitro, amino, cyano; C2 -C6 alkenyl;
- piperidinyl 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N,N-diisopropylaminopiperidine , 4-hydroxypiperidinyl, 4-(N-methylpiperazinyl)piperidinyl, 4-(N-ethylpiperazinyl)piperidinyl, 4-(N-isopropylpiperazinyl) Piperidinyl, 4-(N-acetylpiperazinyl)piperidinyl, 4-(N-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(N-methylsulfonylpiperazinyl) Piperidinyl, 4-(N-(2-hydroxyethyl)piperazinyl)piperidinyl, 4-(N-(2-cyanoethyl)piperazinyl)piperidinyl, 4-(N- (3-hydroxypropyl
- R 2 is selected from:
- R 3 is selected from the group consisting of: hydrogen; C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; C3-C7 cycloalkyl, optionally halogen, nitro, amino, cyano Replace
- R3 may be linked to the N to which it is attached and the C atom on the S1 ring to form a five-membered ring;
- R 4 is selected from the group consisting of: hydrogen; C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; C3-C7 cycloalkyl, optionally halogen, nitro, amino, cyano Replace
- R 5 is selected from:
- Y S, C, P, N, OH, NH 2 or CH 2 ;
- n 0, 1 or 2;
- n 0, 1, 2, 3 or 4;
- R 1 is selected from:
- C1-C6 alkyl optionally substituted by halogen, nitro, cyano; C1-C6 oxyalkyl; C3-C7 cycloalkyl, optionally substituted by halogen, nitro, cyano ; -O-C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; -O-C3-C7 cycloalkyl, optionally halogen, nitro, amino, cyano Substituted; C6-C10 aryl, optionally substituted by halogen, nitro, amino, cyano; -O-C6-C10 aryl, optionally substituted by halogen, nitro, amino, cyano; C2 -C6 alkenyl; 3-N,N-dimethylaminopropenyl, 3-tetrahydropyrrolylpropenyl; amino; hydroxy;
- a five- or six-membered heterocyclic ring comprising one or more heteroatoms selected from N, O and S, optionally a five- or six-membered heterocyclic ring Substituted by C1-C6 alkyl, C1-C6 alkoxy, hydroxy, amino, C1-C6 acyl, cyano, heterocyclic,
- piperidinyl 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N,N-diisopropylaminopiperidine , 4-hydroxypiperidinyl, 4-(N-methylpiperazinyl)piperidinyl, 4-(N-ethylpiperazinyl)piperidinyl, 4-(N-isopropylpiperazinyl) Piperidinyl, 4-(N-acetylpiperazinyl)piperidinyl, 4-(N-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(N-methylsulfonylpiperazinyl) Piperidinyl, 4-(N-(2-hydroxyethyl)piperazinyl)piperidinyl, 4-(N-(2-cyanoethyl)piperazinyl)piperidinyl, 4-(N- (3-hydroxypropyl
- R 2 is selected from the group consisting of: hydrogen, halogen, nitro, amino, cyano; C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; -O-C1- C6 alkyl, which is optionally substituted by halogen, nitro, amino, cyano; C1-C6 oxyalkyl.
- R 3 is selected from the group consisting of: hydrogen; C1-C6 alkyl; C3-C7 cycloalkyl.
- R 4 is selected from the group consisting of: hydrogen; C1-C6 alkyl; C3-C7 cycloalkyl.
- R 5 is selected from the group consisting of: hydrogen, halogen, nitro, amino, cyano; C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; C3-C7 naphthenic A group optionally substituted by a halogen, a nitro group, an amino group, or a cyano group.
- It is a benzene ring group or a thiophene ring group, a furan ring group, a pyridine ring group, an oxazole ring group or a thiazolidine ring group fused to a seven-membered diaza-heterocyclic ring.
- It is a benzene ring group or a pyrazole ring group.
- the pharmaceutically acceptable salt is a mineral or organic acid salt, wherein the mineral acid salt is a hydrochloride, a hydrobromide, a hydroiodide, a nitrate, a hydrogencarbonate. a salt and a carbonate, a sulfate or a phosphate, the organic acid salt being a formate, acetate, propionate, benzoate, maleate, fumarate, succinate, tartaric acid a salt, a citrate, an ascorbate, an alpha-ketoglutarate, an alpha-glycerophosphate, an alkylsulfonate or an arylsulfonate; preferably, the alkylsulfonate is methanesulfonic acid a salt or ethyl sulfonate; the aryl sulfonate being a besylate or p-toluenesulfonate.
- the mineral acid salt is a hydrochloride,
- the invention provides a compound of the following formula I, II, III, IV:
- n1 is selected from 0, 1, 2, 3 or 4;
- R 11 is selected from:
- C1-C6 alkyl optionally substituted by halogen, amino, nitro, cyano; C1-C6 oxyalkyl; C3-C7 cycloalkyl, optionally halogen, amino, nitro a cyano group; a C6-C10 aryl group optionally substituted by halogen, nitro, amino, hydroxy, cyano; C3-C6 alkenyl;
- Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
- hydroxysulfonyl group aminosulfonyl group, methylaminosulfonyl group, ethylaminosulfonyl group, propylaminosulfonyl group, isopropylaminosulfonyl group, cyclopropylaminosulfonyl group, cyclobutylaminosulfonyl group, Cyclopentylaminosulfonyl, piperidinyl-1-sulfonyl, 4-hydroxypiperidinyl-1-sulfonyl, 4-N,N-dimethylpiperidinyl-1-sulfonyl, 4-N ,N-Diethylpiperidinyl-1-sulfonyl, tetrahydropyrrolyl-1-sulfonyl, 3-N,N-dimethyltetrahydropyrrolyl-1-sulfonyl, 3-N,N-Diethyltetrahydropyrrolyl-1-
- Z 2 and Z 3 may form an oxygen-containing substituted or unsubstituted five-membered or six-membered ring; the substituent may be selected from the same substituents as Z 1 described above,
- Z 2 and Z 3 may form a nitrogen-containing substituted or unsubstituted five-membered or six-membered ring; the substituent may be selected from the same substituents as Z 1 described above,
- R 21 is selected from:
- R 31 is selected from:
- R 41 is selected from:
- R 51 is selected from:
- R 11 is selected from:
- Z 3 in R 11 is selected from the group consisting of amino, aminosulfonyl, methylaminosulfonyl, cyclopropylaminosulfonyl, piperidinyl-1-sulfonyl, 4-hydroxypiperidinyl-1 -sulfonyl, 4-N,N-dimethylpiperidinyl-1-sulfonyl, tetrahydropyrrolyl-1-sulfonyl, 3-N,N-dimethyltetrahydropyrrolyl-1-sulfonyl , N-methylpiperazinyl-1-sulfonyl, N-ethylpiperazinyl-1-sulfonyl, morphinolinyl-1-sulfonyl, methylsulfonylamino, ethylsulfonylamino, isopropyl Sulfonamide, vinylsulfonylamino, formate, carbamo
- R 21 is selected from: hydrogen, halo, nitro, amino, cyano; C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; -O-C1- C6 alkyl, which is optionally substituted by halogen, nitro, amino, cyano; C1-C6 oxyalkyl.
- R 31 is selected from the group consisting of: hydrogen; C1-C6 alkyl; C3-C7 cycloalkyl.
- R 41 is selected from the group consisting of: hydrogen; C1-C6 alkyl; C3-C7 cycloalkyl.
- R 51 is selected from: hydrogen, halo, nitro, amino, cyano; C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; -O-C1- C6 alkyl, which is optionally substituted by halogen, nitro, amino, cyano; C1-C6 oxyalkyl.
- n1 is selected from the group consisting of 0, 1, 2, 3.
- n1 is selected from the group consisting of 0, 1, and 2.
- the pharmaceutically acceptable salt is a mineral or organic acid salt, wherein the mineral acid salt is a hydrochloride, a hydrobromide, a hydroiodide, a nitrate, a hydrogencarbonate. a salt and a carbonate, a sulfate or a phosphate, the organic acid salt being a formate, acetate, propionate, benzoate, maleate, fumarate, succinate, tartaric acid Salt, citrate, Ascorbate, ⁇ -ketoglutarate, ⁇ -glycerophosphate, alkylsulfonate or arylsulfonate; preferably, the alkylsulfonate is methanesulfonate or ethylsulfonic acid a salt; the aryl sulfonate is a besylate or p-toluenesulfonate.
- the mineral acid salt is a hydrochloride, a hydrobromide, a hydro
- the present invention provides a compound represented by the following structural formula:
- M2 is selected from 0, 1, 2, 3 or 4;
- N2 is selected from 0, 1, 2, 3 or 4;
- R 12 is selected from:
- R 22 is selected from:
- R 32 is selected from the group consisting of: hydrogen; C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; C3-C7 cycloalkyl, optionally halogen, nitro, amino, cyano Replace
- R 42 is selected from the group consisting of: hydrogen; C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; C3-C7 cycloalkyl, optionally halogen, nitro, amino, cyano Replace
- R 52 is selected from:
- R 12 is selected from:
- R 12 is selected from
- R 22 is selected from: hydrogen, halo, nitro, amino, cyano, C1-C6 alkyl, said C1-C6 alkyl optionally substituted by halogen, nitro, amino, cyano ;-O-C1-C6 alkyl, which is optionally substituted by halogen, nitro, amino, cyano.
- R 22 is selected from the group consisting of hydrogen, halogen, cyano, C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano.
- R 22 is selected from the group consisting of hydrogen, fluorine, chlorine, methyl.
- R 32 is selected from the group consisting of: hydrogen; C1-C6 alkyl; C3-C7 cycloalkyl.
- R 32 is selected from the group consisting of hydrogen, methyl, ethyl, isopropyl, cyclopropyl or cyclopentyl.
- R 42 is selected from the group consisting of: hydrogen; C1-C6 alkyl; C3-C7 cycloalkyl.
- R 42 is selected from the group consisting of hydrogen, methyl, ethyl, isopropyl, cyclopropyl or cyclopentyl.
- R 52 is selected from the group consisting of: hydrogen, halogen, nitro, amino, cyano; C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; C3-C7 naphthenic A group optionally substituted by a halogen, a nitro group, an amino group, or a cyano group.
- R 52 is selected from the group consisting of hydrogen, fluorine, chlorine, amino, methyl, trifluoromethyl.
- m2 is selected from the group consisting of 0, 1, 2, 3.
- m2 is selected from the group consisting of 0, 1, and 2.
- n2 is selected from the group consisting of 0, 1, 2, 3.
- n2 is selected from the group consisting of 0, 1, and 2.
- the pharmaceutically acceptable salt is a mineral or organic acid salt, wherein the mineral acid salt is a hydrochloride, a hydrobromide, a hydroiodide, a nitrate, a hydrogencarbonate. a salt and a carbonate, a sulfate or a phosphate, the organic acid salt being a formate, acetate, propionate, benzoate, maleate, fumarate, succinate, tartaric acid a salt, a citrate, an ascorbate, an alpha-ketoglutarate, an alpha-glycerophosphate, an alkylsulfonate or an arylsulfonate; preferably, the alkylsulfonate is methanesulfonic acid a salt or ethyl sulfonate; the aryl sulfonate being a besylate or p-toluenesulfonate.
- the mineral acid salt is a hydrochloride,
- the present invention provides a compound represented by the following structural formula:
- N3 selected from 0, 1, 2, 3 or 4;
- R 23 is -SO 2 X, wherein X is selected from: hydroxy; C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; C3-C7 cycloalkyl, optionally halogen , nitro, amino, cyano substituted;
- R 13 is selected from the group consisting of: hydrogen; C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; C3-C7 cycloalkyl, optionally halogen, nitro, amino, cyano Replace
- R 33 is selected from:
- R 53 is selected from the group consisting of: hydrogen; C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; C3-C7 cycloalkyl, optionally halogen, nitro, amino, cyano Replace
- R 43 is selected from the group consisting of: hydrogen; C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; C3-C7 cycloalkyl, optionally halogen, nitro, amino, cyano Replace
- R 23 is -SO 2 X, wherein X is selected from the group consisting of: hydroxy; C1-C6 alkyl, optionally substituted with halogen, nitro, amino, cyano.
- R 13 is selected from the group consisting of: hydrogen; C1-C6 alkyl, optionally substituted with halogen, nitro, amino, cyano.
- R 33 is selected from: hydrogen, halo, nitro, amino, cyano, C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; C3-C7 cycloalkyl A group optionally substituted by a halogen, a nitro group, an amino group, or a cyano group.
- R 33 is selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, optionally substituted with halogen, nitro, amino, cyano.
- R 53 is selected from the group consisting of: hydrogen; C1-C6 alkyl, C3-C7 cycloalkyl.
- R 43 is selected from the group consisting of: hydrogen; C1-C6 alkyl, C3-C7 cycloalkyl.
- n3 is selected from the group consisting of 0, 1, 2, 3.
- n3 is selected from the group consisting of 0, 1, and 2.
- the pharmaceutically acceptable salt is a mineral or organic acid salt, wherein the mineral acid salt is a hydrochloride, a hydrobromide, a hydroiodide, a nitrate, a hydrogencarbonate. a salt and a carbonate, a sulfate or a phosphate, the organic acid salt being a formate, acetate, propionate, benzoate, maleate, fumarate, succinate, tartaric acid a salt, a citrate, an ascorbate, an alpha-ketoglutarate, an alpha-glycerophosphate, an alkylsulfonate or an arylsulfonate; preferably, the alkylsulfonate is methanesulfonic acid a salt or ethyl sulfonate; the aryl sulfonate being a besylate or p-toluenesulfonate.
- the mineral acid salt is a hydrochloride,
- the present invention provides a compound represented by the following structural formula:
- N4 is selected from 0, 1 or 2;
- R 14 is selected from:
- R 24 is selected from:
- R 34 is selected from:
- R 44 is selected from:
- R 14 is selected from:
- R 14 is selected from the group consisting of
- R 24 is selected from the group consisting of: hydrogen, halogen, nitro, amino, cyano, C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano ;-O-C1-C6 alkyl, which is optionally substituted by halogen, nitro, amino, cyano.
- R 24 is selected from the group consisting of hydrogen, halogen, cyano, C1-C6 alkyl, and the C1-C6 alkyl group is optionally substituted with halogen, nitro, amino, cyano.
- R 34 is selected from the group consisting of: hydrogen; C1-C6 alkyl; C3-C7 cycloalkyl.
- R 34 is selected from the group consisting of hydrogen, methyl, ethyl, isopropyl, cyclopropyl or cyclopentyl.
- R 44 is selected from the group consisting of: hydrogen; C1-C6 alkyl; C3-C7 cycloalkyl.
- R 44 is selected from the group consisting of hydrogen, methyl, ethyl, isopropyl, cyclopropyl or cyclopentyl.
- n4 is selected from the group consisting of 0,1.
- the pharmaceutically acceptable salt is a mineral or organic acid salt, wherein the mineral acid salt is a hydrochloride, a hydrobromide, a hydroiodide, a nitrate, a hydrogencarbonate. a salt and a carbonate, a sulfate or a phosphate, the organic acid salt being a formate, acetate, propionate, benzoate, maleate, fumarate, succinate, tartaric acid a salt, a citrate, an ascorbate, an alpha-ketoglutarate, an alpha-glycerophosphate, an alkylsulfonate or an arylsulfonate; preferably, the alkylsulfonate is methanesulfonic acid a salt or ethyl sulfonate; the aryl sulfonate being a besylate or p-toluenesulfonate.
- the mineral acid salt is a hydrochloride,
- the present invention provides a compound represented by the following structural formula:
- M5 is selected from 0, 1, 2, 3 or 4;
- N5 is selected from 0, 1 or 2;
- R 15 and R 25 are independently selected from:
- R 15 and R 25 together with the N atom to which they are attached form a six-membered heterocyclic ring comprising one or more heteroatoms selected from N, O and S, optionally substituted by C1-C6 Alkyl, hydroxy, amino substituted;
- R 35 is selected from:
- R 45 is selected from:
- R 55 is selected from:
- R 65 is selected from:
- R 15 is selected from: hydrogen; C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; -SO 2 C1-C6 alkyl, optionally halogen , nitro, amino, cyano substituted; -SO 2 C2-C6 alkenyl, optionally substituted by halogen, nitro, amino, cyano; -COC1-C6 alkyl, optionally halogen, nitrate Substituent, amino, cyano substituted; -COC2-C6 alkenyl, which is optionally substituted by halogen, nitro, amino, cyano.
- R 25 is selected from the group consisting of: hydrogen; C1-C6 alkyl, optionally substituted with halogen, nitro, amino, cyano.
- R 25 is hydrogen
- R 15 and R 25 together with the N atom to which they are attached form a six-membered heterocyclic ring comprising one or more heteroatoms selected from N, O and S, optionally wherein the six-membered heterocyclic ring is optionally It is substituted by a C1-C6 alkyl group, a hydroxyl group, or an amino group.
- R 15 and R 25 together with the N atom to which they are attached form a piperidine ring, a piperazine ring, optionally a C1-C6 alkyl group, a hydroxyl group. Replace.
- the, R 35 is selected from: hydrogen, halo, nitro, amino, cyano, C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; C3-C7 cycloalkyl An alkyl group, which is optionally substituted by halogen, nitro, amino, cyano.
- R 35 is selected from the group consisting of hydrogen, halogen, nitro, amino, cyano, C1-C6 alkyl.
- R 45 is selected from the group consisting of: hydrogen; C1-C6 alkyl; C3-C7 cycloalkyl.
- R 45 is selected from the group consisting of hydrogen, methyl, ethyl, isopropyl, cyclopropyl or cyclopentyl.
- R 55 is selected from the group consisting of: hydrogen; C1-C6 alkyl; C3-C7 cycloalkyl.
- R 55 is selected from the group consisting of hydrogen, methyl, ethyl, isopropyl, cyclopropyl or cyclopentyl.
- R 65 is selected from: hydrogen, halo, nitro, amino, cyano, C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; C3-C7 cycloalkyl A group optionally substituted by a halogen, a nitro group, an amino group, or a cyano group.
- R 65 is selected from the group consisting of hydrogen, halogen, nitro, amino, cyano, C1-C6 alkyl.
- m5 is selected from the group consisting of 0, 1, 2, 3.
- m5 is selected from the group consisting of 0, 1, and 2.
- n5 is selected from the group consisting of 0,1.
- n5 is zero.
- the pharmaceutically acceptable salt is a mineral or organic acid salt, wherein the mineral acid salt is a hydrochloride, a hydrobromide, a hydroiodide, a nitrate, a hydrogencarbonate. a salt and a carbonate, a sulfate or a phosphate, the organic acid salt being a formate, acetate, propionate, benzoate, maleate, fumarate, succinate, tartaric acid a salt, a citrate, an ascorbate, an alpha-ketoglutarate, an alpha-glycerophosphate, an alkylsulfonate or an arylsulfonate; preferably, the alkylsulfonate is methanesulfonic acid a salt or ethyl sulfonate; the aryl sulfonate being a besylate or p-toluenesulfonate.
- the mineral acid salt is a hydrochloride,
- the present invention provides a compound represented by the following structural formula:
- N6 is selected from 0, 1 or 2;
- R 16 is selected from:
- R 26 is selected from:
- R 36 is selected from the group consisting of: hydrogen; C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; C3-C7 cycloalkyl, optionally halogen, nitro, amino, cyano Replace
- R 46 is selected from the group consisting of: hydrogen; C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; C3-C7 cycloalkyl, optionally halogen, nitro, amino, cyano Replace
- R 16 is selected from the group consisting of: hydrogen; C1-C6 alkyl; C3-C7 cycloalkyl; -SO 2 C1-C6 alkyl; -SO 2 C2-C6 alkenyl; -COC1-C6 alkyl , which is optionally substituted by halogen, nitro, amino, cyano; -COC2-C6 alkenyl, which is optionally substituted by halogen, nitro, amino, cyano.
- R 16 is selected from the group consisting of hydrogen; hydrogen; methyl, ethyl, isopropyl, cyclopropyl; methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, vinylsulfonyl; acetyl , chloroacetyl, bromoacetyl, acryloyl, 4-N,N-dimethylamino-2-butenoyl, 4-tetrahydropyrrolyl-2-butenoyl.
- R 26 is selected from: hydrogen, halo, nitro, amino, cyano, C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; C3-C7 cycloalkyl A group optionally substituted by a halogen, a nitro group, an amino group, or a cyano group.
- R 26 is selected from the group consisting of hydrogen, halogen, nitro, amino, cyano, C1-C6 alkyl.
- R 36 is selected from the group consisting of: hydrogen; C1-C6 alkyl; C3-C7 cycloalkyl.
- R 46 is selected from the group consisting of: hydrogen; C1-C6 alkyl; C3-C7 cycloalkyl.
- n6 is selected from the group consisting of 0, 1.
- n6 is zero.
- the pharmaceutically acceptable salt is a mineral or organic acid salt, wherein the mineral acid salt is a hydrochloride, a hydrobromide, a hydroiodide, a nitrate, a hydrogencarbonate. a salt and a carbonate, a sulfate or a phosphate, the organic acid salt being a formate, acetate, propionate, benzoate, maleate, fumarate, succinate, tartaric acid a salt, a citrate, an ascorbate, an alpha-ketoglutarate, an alpha-glycerophosphate, an alkylsulfonate or an arylsulfonate; preferably, the alkylsulfonate is methanesulfonic acid a salt or ethyl sulfonate; the aryl sulfonate being a besylate or p-toluenesulfonate.
- the mineral acid salt is a hydrochloride,
- the present invention provides a compound represented by the following structural formula:
- N7 is selected from 0, 1 or 2;
- R 17 is selected from:
- R 27 is selected from:
- R 37 is selected from:
- R 47 is selected from:
- R 17 is selected from the group consisting of hydrogen; hydrogen; C1-C6 alkyl; C3-C7 cycloalkyl; -SO 2 C1-C6 alkyl; -SO 2 C2-C6 alkenyl; -COC1-C6 alkane a group optionally substituted by halogen, nitro, amino, cyano; -COC2-C6 alkenyl, optionally substituted by halogen, nitro, amino, cyano.
- R 17 is selected from the group consisting of hydrogen; hydrogen; methyl, ethyl, isopropyl, cyclopropyl; methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, vinylsulfonyl; acetyl , chloroacetyl, bromoacetyl, acryloyl, 4-N,N-dimethylamino-2-butenoyl, 4-tetrahydropyrrolyl-2-butenoyl.
- R 27 is selected from the group consisting of: hydrogen, halogen, nitro, amino, cyano, C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; C3-C7 naphthenic A group optionally substituted by a halogen, a nitro group, an amino group, or a cyano group.
- R 27 is selected from the group consisting of hydrogen, halogen, nitro, amino, cyano, C1-C6 alkyl.
- R 37 is selected from the group consisting of: hydrogen; C1-C6 alkyl; C3-C7 cycloalkyl.
- R 47 is selected from the group consisting of: hydrogen; C1-C6 alkyl; C3-C7 cycloalkyl.
- n7 is selected from the group consisting of 0, 1.
- n7 is zero.
- the pharmaceutically acceptable salt is a mineral or organic acid salt, wherein the mineral acid salt is a hydrochloride, a hydrobromide, a hydroiodide, a nitrate, a hydrogencarbonate. a salt and a carbonate, a sulfate or a phosphate, the organic acid salt being a formate, acetate, propionate, benzoate, maleate, fumarate, succinate, tartaric acid a salt, a citrate, an ascorbate, an alpha-ketoglutarate, an alpha-glycerophosphate, an alkylsulfonate or an arylsulfonate; preferably, the alkylsulfonate is methanesulfonic acid a salt or ethyl sulfonate; the aryl sulfonate being a besylate or p-toluenesulfonate.
- the mineral acid salt is a hydrochloride,
- the present invention provides a compound represented by the following structural formula:
- N8 is selected from 0, 1 or 2;
- R 18 is selected from:
- R 28 is selected from:
- R 38 is selected from the group consisting of: hydrogen; C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; C3-C7 cycloalkyl, optionally halogen, nitro, amino, cyano Replace
- R 48 is selected from the group consisting of: hydrogen; C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; C3-C7 cycloalkyl, optionally halogen, nitro, amino, cyano Replace
- R 18 is selected from:
- R 18 is selected from the group consisting of
- R 28 is selected from the group consisting of: hydrogen, halogen, nitro, amino, cyano, C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; C3-C7 naphthenic A group optionally substituted by a halogen, a nitro group, an amino group, or a cyano group.
- R28 is selected from the group consisting of hydrogen, halogen, nitro, amino, cyano, C1-C6 alkyl.
- R 38 is selected from the group consisting of: hydrogen; C1-C6 alkyl; C3-C7 cycloalkyl.
- R 48 is selected from the group consisting of: hydrogen; C1-C6 alkyl; C3-C7 cycloalkyl.
- n8 is selected from the group consisting of 0, 1.
- n8 is zero.
- the pharmaceutically acceptable salt is a mineral or organic acid salt, wherein the mineral acid salt is a hydrochloride, a hydrobromide, a hydroiodide, a nitrate, a hydrogencarbonate. a salt and a carbonate, a sulfate or a phosphate, the organic acid salt being a formate, acetate, propionate, benzoate, maleate, fumarate, succinate, tartaric acid a salt, a citrate, an ascorbate, an alpha-ketoglutarate, an alpha-glycerophosphate, an alkylsulfonate or an arylsulfonate; preferably, the alkylsulfonate is methanesulfonic acid a salt or ethyl sulfonate; the aryl sulfonate being a besylate or p-toluenesulfonate.
- the mineral acid salt is a hydrochloride,
- the present invention provides a compound represented by the following structural formula:
- N9 is selected from 0, 1, 2 or 3;
- R 19 is selected from:
- R 29 is selected from:
- R 49 is selected from the group consisting of: hydrogen; C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; C3-C7 cycloalkyl, optionally halogen, nitro, amino, cyano Replace
- R 19 is selected from the group consisting of hydrogen; C1-C6 alkyl; C3-C7 cycloalkyl; -SO 2 C1-C6 alkyl; -SO 2 C2-C6 alkenyl; -COC1-C6 alkyl, It is optionally substituted by halogen, nitro, amino, cyano; -COC2-C6 alkenyl, which is optionally substituted by halogen, nitro, amino, cyano.
- R 19 is selected from the group consisting of methyl, ethyl, isopropyl, cyclopropyl; methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, vinylsulfonyl; acetyl, chloroacetyl , bromoacetyl, acryloyl, 4-N,N-dimethylamino-2-butenoyl, 4-tetrahydropyrrolyl-2-butenoyl.
- R 29 is selected from the group consisting of hydrogen, halogen, nitro, amino, cyano, C1-C6 alkyl.
- R 29 is selected from the group consisting of hydrogen, fluorine, chlorine, bromine, nitro, amino, cyano, methyl.
- R 49 is selected from the group consisting of: hydrogen; C1-C6 alkyl; C3-C7 cycloalkyl.
- n9 is selected from the group consisting of 0, 1, 2.
- n9 is selected from the group consisting of 0,1.
- the pharmaceutically acceptable salt is a mineral or organic acid salt, wherein the mineral acid salt is a hydrochloride, a hydrobromide, a hydroiodide, a nitrate, a hydrogencarbonate. a salt and a carbonate, a sulfate or a phosphate, the organic acid salt being a formate, acetate, propionate, benzoate, maleate, fumarate, succinate, tartaric acid a salt, a citrate, an ascorbate, an alpha-ketoglutarate, an alpha-glycerophosphate, an alkylsulfonate or an arylsulfonate; preferably, the alkylsulfonate is methanesulfonic acid a salt or ethyl sulfonate; the aryl sulfonate being a besylate or p-toluenesulfonate.
- the mineral acid salt is a hydrochloride,
- the present invention provides a compound represented by the following structural formula:
- N0 is selected from 0, 1, 2 or 3;
- R 10 is selected from:
- R 20 is selected from:
- R 40 is selected from the group consisting of: hydrogen; C1-C6 alkyl, optionally substituted by halogen, nitro, amino, cyano; C3-C7 cycloalkyl, optionally halogen, nitro, amino, cyano Replace
- R 10 is selected from -SO 2 C1-C6 alkyl, which is optionally substituted with halogen, nitro, amino, cyano; -SO 2 NH 2 .
- R 10 is -SO 2 NH 2 .
- R 20 is selected from the group consisting of hydrogen, halogen, nitro, amino, cyano, C1-C6 alkyl.
- R 20 is selected from the group consisting of hydrogen, fluorine, chlorine, bromine, nitro, amino, cyano, methyl.
- R 40 is selected from the group consisting of: hydrogen; C1-C6 alkyl; C3-C7 cycloalkyl.
- n0 is selected from the group consisting of 0, 1, and 2.
- n0 is selected from the group consisting of 0,1.
- the pharmaceutically acceptable salt is a mineral or organic acid salt, wherein the mineral acid salt is a hydrochloride, a hydrobromide, a hydroiodide, a nitrate, a hydrogencarbonate. a salt and a carbonate, a sulfate or a phosphate, the organic acid salt being a formate, acetate, propionate, benzoate, maleate, fumarate, succinate, tartaric acid a salt, a citrate, an ascorbate, an alpha-ketoglutarate, an alpha-glycerophosphate, an alkylsulfonate or an arylsulfonate; preferably, the alkylsulfonate is methanesulfonic acid a salt or ethyl sulfonate; the aryl sulfonate being a besylate or p-toluenesulfonate.
- the mineral acid salt is a hydrochloride,
- the C1-C6 oxyalkyl group means a group in which a C1-C6 alkyl skeleton is substituted by one or more C1-C6 alkoxy groups, for example, a methoxyethyl group, a methoxy group. Ethyl ethoxymethyl and the like.
- C6-10 aryl refers to a mono-, di- or poly-carbacyclic hydrocarbon having from 1 to 2 ring systems which are optionally further fused or linked to each other by a single bond, wherein said carbocyclic ring At least one is “aromatic", wherein the term “aromatic” refers to a fully conjugated ⁇ -electron bond system.
- the aryl ring can be optionally further fused or attached to the aromatic and non-aromatic carbocyclic and heterocyclic rings.
- Non-limiting examples of such aryl groups are phenyl, alpha- or beta-naphthyl.
- heteroaryl refers to an aromatic heterocyclic ring, typically a 5- to 8-membered heterocyclic ring having from 1 to 3 heteroatoms selected from N, O or S; heteroaryl rings may optionally be Further fused or linked to aromatic and non-aromatic carbocyclic and heterocyclic rings.
- Non-limiting examples of such heteroaryl groups are, for example, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, fluorenyl, imidazolyl, thiazolyl, isothiazolyl, thiazolyl, pyrrolyl, benzene -pyrrolyl, furyl, phenyl-furanyl, oxazolyl, isoxazolyl, pyrazolyl, thienyl, benzothienyl, isoindoline, benzimidazolyl, carbazolyl , quinolyl, isoquinolyl, 1,2,3-triazolyl, 1-phenyl-1,2,3-triazolyl, 2,3-dihydroindenyl, 2,3-di Hydrobenzofuranyl, 2,3-dihydrobenzothienyl, benzopyranyl, 2,3-dihydrobenzoxazinyl, 2,3
- heterocyclyl (also referred to as “heterocycloalkyl”) refers to 3-, 4-, 5-, 6- and 7-membered saturated or partially unsaturated carbocyclic rings wherein one or more carbon atoms Substituted by heteroatoms such as nitrogen, oxygen and sulfur.
- heterocyclic groups are, for example, pyran, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazolidine, pyrazoline, thiazoline, thiazolidine, dihydrofuran, tetrahydrofuran, 1,3- Dioxolane, piperidine, piperazine, morpholine, morphinolyl, tetrahydropyrrolyl, thiomorpholinyl and the like.
- C 1 -C 6 alkyl refers to any straight or branched chain group containing from 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, Isobutyl, tert-butyl, sec-butyl, n-pentyl, tert-amyl, n-hexyl and the like.
- C 3 -C 7 cycloalkyl refers to a 3- to 7-membered all-carbon monocyclic ring which may contain one or more double bonds but does not have a fully conjugated ⁇ - electronic system.
- cycloalkyl groups are, but are not limited to, cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene, cyclohexadiene, cycloheptane, cycloheptene, cycloheptadiene.
- C 2 -C 6 alkenyl refers to any straight or branched chain group containing from 2 to 6 carbon atoms and containing at least one alkenyl group, such as vinyl, allyl, 1-propene.
- a base an isopropenyl group, a 1-butenyl group, a 2-butenyl group, a 3-butenyl group, a 2-pentenyl group, a 1-hexenyl group or the like.
- C 2 -C 6 alkynyl refers to any straight or branched chain group containing from 2 to 6 carbon atoms and containing at least one alkynyl group, for example ethynyl, 2-propynyl, 4-pentyl Alkynyl and the like.
- C 1 -C 5 alkyl refers to any straight or branched chain group containing from 1 to 5 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl Base, isobutyl, tert-butyl, sec-butyl, n-pentyl, tert-amyl and the like.
- each of the above substituents may be further substituted with one or more of the above-exemplified groups, if appropriate.
- halogen atom refers to a fluorine, chlorine, bromine or iodine atom.
- cyano refers to the -CN residue.
- nitro refers to a -NO 2 group.
- alkoxy refers to any of the above C 1 -C 6 alkyl groups, C 3 -C 7 A cycloalkyl, aryl or heterocyclic group attached to the remainder of the molecule through an oxygen atom (-O-).
- any group whose name is a compound name, such as "arylamino”, shall mean a moiety conventionally derived therefrom, for example, an amino group substituted with an aryl group.
- aryl group is as defined above.
- any term such as an alkylthio group, an alkylamino group, a dialkylamino group, an alkoxycarbonyl group, an alkoxycarbonylamino group, a heterocyclic carbonyl group, a heterocyclic carbonylamino group, a cycloalkyloxycarbonyl group or the like includes a group.
- alkyl, alkoxy, aryl, C 3 -C 7 cycloalkyl and heterocyclyl moieties are as defined above.
- prodrug refers to a derivative that can be hydrolyzed, oxidized, or otherwise reacted under biological conditions (in vitro or in vivo) to provide a compound of the invention. Prodrugs undergo this reaction to become active compounds only under biological conditions, or they are active in their unreacted form. Prodrugs can generally be prepared using well-known methods, such as those described in 1 Burger's Medicinal Chemistry and Drug Discovery (1995) 172-178, 949-982 (Manfred E. Wolff, ed., 5th Edition).
- the term "pharmaceutically acceptable salt of a compound of formula (I)" is an organic acid addition salt formed from an organic acid forming a pharmaceutically acceptable anion, including but not limited to formate, Acetate, propionate, benzoate, maleate, fumarate, succinate, tartrate, citrate, ascorbate, alpha-ketoglutarate, alpha-glycerophosphate Or an alkyl sulfonate or an aryl sulfonate; preferably, the alkyl sulfonate is a methanesulfonate or ethyl sulfonate; the aryl sulfonate is a besylate or a Tosylate.
- Suitable inorganic salts can also be formed including, but not limited to, hydrochloride, hydrobromide, hydroiodide, nitrate, bicarbonate and carbonate, sulfate or phosphate, and the like.
- compositions can be obtained using standard procedures well known in the art, for example, by reacting a sufficient amount of a basic compound with a suitable acid that provides a pharmaceutically acceptable anion.
- treating generally refers to obtaining the desired pharmacological and/or physiological effects.
- the effect may be prophylactic according to the prevention of the disease or its symptoms in whole or in part; and/or may be therapeutic according to the partial or complete stabilization or cure of the disease and/or side effects due to the disease.
- treatment encompasses any treatment for a patient's condition, including: (a) prevention of a disease or condition in a patient who is susceptible to an infectious disease or condition but has not yet diagnosed the disease; (b) inhibition of the symptoms of the disease, That is, to prevent its development; or (c) to alleviate the symptoms of the disease, that is, to cause the disease or symptoms to degenerate.
- the compound, a stereoisomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof wherein the compound is the following example One of the compounds described.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising the compound according to any one of the above aspects, a stereoisomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvent And pharmaceutically acceptable carrier, Release or excipient.
- a method of preparing the pharmaceutical composition comprises incorporating a suitable pharmaceutical excipient, carrier, diluent, and the like.
- the pharmaceutical preparations of the invention are prepared in a known manner, including conventional methods of mixing, dissolving or lyophilizing.
- the compounds of the present invention can be formulated into pharmaceutical compositions and administered to a patient in a variety of ways suitable for the chosen mode of administration, for example, orally or parenterally (by intravenous, intramuscular, topical or subcutaneous routes).
- the compounds of the invention may be administered systemically, for example, orally, in association with a pharmaceutically acceptable carrier such as an inert diluent or an assimilable edible carrier. They can be enclosed in hard or soft shell gelatin capsules and can be compressed into tablets.
- a pharmaceutically acceptable carrier such as an inert diluent or an assimilable edible carrier. They can be enclosed in hard or soft shell gelatin capsules and can be compressed into tablets.
- the active compound may be combined with one or more excipients and in the form of swallowable tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. use.
- Such compositions and preparations should contain at least 0.1% of active compound.
- the ratio of such compositions and formulations may of course vary and may range from about 1% to about 99% by weight of a given unit dosage form.
- the amount of active compound is such that an effective dosage level can be obtained.
- Tablets, lozenges, pills, capsules and the like may also contain: a binder such as tragacanth, acacia, corn starch or gelatin; an excipient such as dicalcium phosphate; a disintegrating agent such as corn starch, Potato starch, alginic acid, etc.; a lubricant such as magnesium stearate; and a sweetener such as sucrose, fructose, lactose or aspartame; or a flavoring agent such as mint, wintergreen or cherry.
- a binder such as tragacanth, acacia, corn starch or gelatin
- an excipient such as dicalcium phosphate
- a disintegrating agent such as corn starch, Potato starch, alginic acid, etc.
- a lubricant such as magnesium stearate
- a sweetener such as sucrose, fructose, lactose or aspartame
- a flavoring agent such as mint, wintergreen or cherry
- any material used to prepare any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed.
- the active compound can be incorporated into sustained release formulations and sustained release devices.
- the active compound can also be administered intravenously or intraperitoneally by infusion or injection.
- An aqueous solution of the active compound or a salt thereof can be prepared, optionally mixed with a non-toxic surfactant.
- Dispersing agents in glycerol, liquid polyethylene glycols, triacetin and mixtures thereof, and oils can also be prepared. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- Pharmaceutical dosage forms suitable for injection or infusion may include sterile aqueous solutions or dispersions of the active ingredient (optionally encapsulated in liposomes) containing the immediate formulation of a suitable injectable or injectable solution or dispersing agent. Or sterile powder. In all cases, the final dosage form must be sterile, liquid, and stable under the conditions of manufacture and storage.
- the liquid carrier can be a solvent or liquid dispersion medium including, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like), vegetable oils, non-toxic glycerides, and suitable mixtures thereof.
- Proper fluidity can be maintained, for example, by liposome formation, by maintaining the desired particle size in the case of a dispersing agent, or by the use of a surfactant.
- the action of preventing microorganisms can be produced by various antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
- isotonic agents such as sugars, buffers or sodium chloride.
- Prolonged absorption of the injectable compositions can be brought about by the use of compositions that delay the absorbent (for example, aluminum monostearate and gelatin).
- Sterile injectable solutions are prepared by combining the required active compound in a suitable solvent with the various other ingredients enumerated above, followed by filter sterilization.
- the preferred preparation methods are vacuum drying and lyophilization techniques which result in a powder of the active ingredient plus any additional ingredients present in the previously sterile filtration solution. .
- Useful solid carriers include comminuted solids (e.g., talc, clay, microcrystalline cellulose, silica, alumina, etc.).
- Useful liquid carriers include water, ethanol or ethylene glycol or a water-ethanol/ethylene glycol mixture, and the compounds of the present invention may be dissolved or dispersed in an effective amount, optionally with the aid of a non-toxic surfactant.
- Adjuvants such as fragrances
- additional antimicrobial agents can be added to optimize the properties for a given use.
- Thickeners can also be used with liquid carriers to form coatable pastes, gels, ointments , soap, etc., used directly on the user's skin.
- the therapeutic requirements of a compound or an active salt or derivative thereof depend not only on the particular salt selected, but also on the mode of administration, the nature of the disease to be treated, and the age and condition of the patient, ultimately depending on the attending physician or clinician decision.
- unit dosage form is a unit dispersion unit containing a unit dosage unit suitable for administration to humans and other mammalian bodies.
- the unit dosage form can be a capsule or tablet, or a plurality of capsules or tablets.
- the amount of unit dose of the active ingredient may vary or be adjusted between about 0.1 and about 1000 mg or more, depending on the particular treatment involved.
- milk liposomes such as milk liposomes, microspheres and nanospheres
- microparticle dispersion systems including polymeric micelles, nanoemulsions, submicroemuls Agents prepared from microcapsules, microspheres, liposomes, and niosomes (also known as nonionic surfactant vesicles).
- the present invention provides a method for preparing the compound according to any one of the above technical solutions, comprising the steps of:
- R 31 Z symbol Z represents a leaving group such as halogen, mesylate, triflate,
- Reaction conditions (a) substitution conditions of basic conditions (such as diisopropylethylamine, triethylamine, potassium carbonate, etc.) or acidic conditions (trifluoroacetic acid, hydrochloric acid, etc.); (b) nitro reduction and amide a cyclization reaction (such as iron powder / acetic acid, etc.); (c) basic conditions (such as sodium hydrogen, etc.); (d) acidic conditions (trifluoroacetic acid, hydrochloric acid, etc.) or palladium-catalyzed amination; or
- Reaction conditions (a) substitution reaction of basic conditions (such as diisopropylethylamine, triethylamine, potassium carbonate, etc.); (b) nitro reduction reaction (such as iron powder / acetic acid, etc.); (c) Ester hydrolysis reaction of basic conditions (such as lithium hydroxide, etc.); (d) amide condensation cyclization (such as 2-(7-azobenzotriazole)-N,N,N',N'-tetra a condensation reagent such as a urea hexafluorophosphate; (e) a basic condition (such as sodium hydrogen); (f) an acidic condition (trifluoroacetic acid, hydrochloric acid, etc.) or a palladium-catalyzed amination reaction;
- basic conditions such as diisopropylethylamine, triethylamine, potassium carbonate, etc.
- nitro reduction reaction such as iron powder / acetic acid, etc.
- Reaction conditions (a) substitution reaction of basic conditions (such as diisopropylethylamine, triethylamine, potassium carbonate, etc.); (b) nitro reduction reaction (such as iron powder / acetic acid, etc.); (c) Ester hydrolysis reaction of basic conditions (such as lithium hydroxide, etc.); (d) amide condensation cyclization (such as 2-(7-azobenzotriazole)-N,N,N',N'-tetra a condensation reagent such as a urea hexafluorophosphate; (e) a basic condition (such as sodium hydrogen); (f) an acidic condition (trifluoroacetic acid, hydrochloric acid, etc.) or a palladium-catalyzed amination reaction;
- basic conditions such as diisopropylethylamine, triethylamine, potassium carbonate, etc.
- nitro reduction reaction such as iron powder / acetic acid, etc.
- Reaction conditions (a) basic conditions (such as diisopropylethylamine, etc.); (b) nitro reduction and amide cyclization (such as iron powder / acetic acid, etc.); (c) basic conditions (such as sodium) Hydrogen, etc.; (d) acidic conditions (trifluoroacetic acid, hydrochloric acid, etc.) or palladium catalyzed amination.
- basic conditions such as diisopropylethylamine, etc.
- nitro reduction and amide cyclization such as iron powder / acetic acid, etc.
- basic conditions such as sodium
- Hydrogen etc.
- acidic conditions trifluoroacetic acid, hydrochloric acid, etc.
- the present invention provides a compound according to any one of the above aspects, a stereoisomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, and a compound comprising the same
- the pharmaceutical composition is prepared for promoting tissue And the use of organ regeneration and repair, promoting stem cell proliferation and adult cell dedifferentiation, immunosuppression, prevention or treatment of diseases associated with neurological disorders in vivo and ischemic vascular diseases.
- the promoting tissue and organ regeneration and repair are liver regeneration and repair, intestinal regeneration and repair, cardiac regeneration and repair, skin regeneration and repair; wherein the prevention or treatment is related to an in vivo neurological disorder. Alzheimer's disease, multiple sclerosis, Parkinson's disease, stroke.
- the compounds of the invention are synthesized using the methods described herein or other methods well known in the art.
- Thin layer chromatography was carried out on a silica gel GF254 precoated plate (Qingdao Marine Chemical Plant). Column chromatography was carried out by silica gel (300-400 mesh, Yantai Zhihuang Silica Gel Development Reagent Factory) under medium pressure or by column chromatography using a pre-packed silica gel cartridge (ISCO or Welch) using an ISCO Combiflash Rf200 rapid purification system. The ingredients were developed by UV light ( ⁇ : 254 nm) and by iodine vapor.
- the compounds were prepared by preparative HPLC on a Waters Symmetry C18 (19 x 50 mm, 5 ⁇ m) column or via a Waters X Terra RP 18 (30 x 150 mm, 5 ⁇ m) column using Waters preparative HPLC equipped with a 996 Waters PDA detector. 600 and Micromass mod. ZMD single quadrupole mass spectrometry (electrospray ionization, cationic mode).
- Method 1 Phase A: 0.1% TFA / MeOH 95/5 ; phase B: MeOH / H 2 O 95/5 . Gradient: 10 to 90% B for 8 min, 90% B 2 min; flow rate 20 mL/min.
- Method 2 Phase A: 0.05% NH 4 OH / MeOH 95/5; phase B: MeOH / H 2 O 95/5 . Gradient: 10 to 100% B for 8 min, maintaining 100% B 2 min. The flow rate was 20 mL/min.
- Electrospray (ESI) mass spectra were obtained on a Finnigan LCQ ion trap.
- HPLC-UV-MS analysis for evaluating compound purity was performed by combining an ion trap MS apparatus with an HPLC system SSP4000 (Thermo Separation Products) equipped with an autosampler LC Pal (CTC Analytics) and a UV6000LP diode array Detector (UV detection 215-400 nm). Device control, data acquisition and processing with Xcalibur 1.2 software (Finnigan). HPLC chromatography was carried out at room temperature and a flow rate of 1 mL/min using a Waters X Terra RP 18 column (4.6 x 50 mm; 3.5 [mu]m).
- Mobile phase A was ammonium acetate 5 mM buffer (pH 5.5 with acetic acid): acetonitrile 90:10
- mobile phase B ammonium acetate 5 mM buffer (pH 5.5 with acetic acid): acetonitrile 10:90; gradient 0 to 100% B Perform for 7 minutes and then maintain 100% B for 2 minutes before rebalancing.
- Derivatives of Compound Series III can be synthesized by the method of Series II.
- the starting material 10 (1.17 g, 6.6 mmol), N,N-diisopropylethylamine (3.37 mL, 19.8 mmol) was dissolved in 30 mL of isopropanol, stirred at room temperature, and then added to 2 mL of isopropanol.
- 4-Dichloro-5-nitropyrimidine (1.94 g, 10.0 mmol)
- the final system was transferred to an oil bath preheated to 50 ° C, and the reaction was stirred until the reaction was completed by LC-MS and TLC.
- the control group contained no ATP or kinase
- reaction solution was decanted to terminate the kinase reaction and washed 4 times with a rinse solution for 5 minutes each time;
- the primary antibody (Cell Signalling, #8699) phosphorylated against the 35th threonine of Mob1 was diluted 1:1000 in blocking solution, added to a 96-well plate, reacted at room temperature for 3 hours, and rinsed 4 times;
- the absorbance at 450 nM per well was measured using a microplate reader (VARIOSKAN FLASH, Thermo). Set three flats for each set of experiments The final concentration was 1% DMSO as a negative control, and the ATP-free reaction system was used as a blank control with a concentration gradient of 10, 3.33, 1.11, 0.37, 0.123, 0.04, 0.014, 0.004, 0 ⁇ M.
- the inhibition rate of kinase activity is calculated by the following formula:
- IC 50 value calculation Compound of Semi kinase inhibitory concentrations GradPad Prism 5 software using a kinase activity according to the inhibition rate measurements.
- the reagents used are formulated as follows:
- Coating buffer 0.1M NaHCO 3 , 0.033M Na 2 CO 3 , pH 9.5
- Reaction buffer 40 mM Hepes-NaOH (pH 7.4), 10 mM MgCl 2 , 1 mM dithiothreitol (DTT), 1 mM NaF, 1 mM Na 3 VO 4 , 1 mM ⁇ -glycerophosphate
- Blocking solution 1% BSA dissolved in PBS
- Compound II-1 can effectively promote liver regeneration in partial hepatectomy
- Compound II-1 can effectively promote intestinal repair in a model of intestinal damage induced by Dextran sulfate sodium (DSS)
- mice induced by DSS The intestinal damage model of mice induced by DSS was used to study the effect of compound II-1 on intestinal damage repair.
- the DAI value is calculated as follows: the integrity of the feces (value 0 -3,0: complete dry fecal pellets; 1: softer particles; 2: loose, moist feces; 3: diarrhea); intestinal bleeding with o-tolidine (value 0-3, 0 : Adding the detection reagent for 2 minutes, the sample has no color development; 1: Adding the detection reagent, the sample changes from light blue to blue within 10 seconds; 2: After adding the detection reagent, the sample gradually changes from light brown to clear brown blue And the blood color is visible to the naked eye in the feces; 3: After adding the test reagent, the sample quickly turns brownish blue, and there is obvious blood and bleeding in the anus and feces.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (12)
- 以下通式的化合物,其为以下:其中,n1选自0,1,2,3或4;优选n1选自0,1,2,3;更优选n1选自0,1,2;R11选自:1)C1-C6烷基,其任选地被卤素、氨基、硝基、氰基取代;C1-C6含氧烷基;C3-C7环烷基,其任选地被卤素、氨基、硝基、氰基取代;C6-C10芳基,其任选地被卤素、硝基、氨基、羟基、氰基取代;C3-C6烯基;2)2-N,N-二甲基氨基乙基,2-羟基乙基,2-N,N-二乙基氨基乙基,2-N,N-二异丙基氨基乙基,2-吗啡啉基乙基,2-硫代吗啉基乙基,2-(4-N-甲基哌嗪基)乙基,3-N,N-二甲基氨基丙基,3-N,N-二乙基氨基丙基,3-N,N-二异丙基氨基丙基,3-吗啡啉基丙基,3-硫代吗啉基丙基,3-(4-N-甲基哌嗪)基丙基,4-N,N-二甲基氨基环己基,4-N,N-二乙基氨基环己基,N-甲基-4-哌啶基,N-乙基-4-哌啶基,N-异丙基-4-哌啶基,1,3-二甲基-5-吡唑基,1-甲基-4-吡唑基,3-甲基-5-异噁唑啉基,1-(N-甲基-4-哌啶基)-4-吡唑基,1-(N-叔丁氧甲酰基-4-哌啶基)-4-吡唑基;(1)氢,卤素,硝基,氨基,羟基,氰基,(2)C1-C6烷基,C1-C6烷氧基,C1-C6含氧烷基,C1-C6含氟烷基,C1-C6含氟烷氧基,4-哌啶基,N-甲基-4-哌啶基,(3)N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基,2-N,N-二甲基氨基乙基氨基,2-吗啡啉基乙基氨基,2-硫代吗啉基乙基氨基,2-(4-N-甲基哌嗪基)乙基氨基,3-N,N-二甲基氨基丙基氨基,3-N,N-二乙基氨基丙基氨基,3-N,N-二异丙基氨基丙基氨基,3-吗啡啉基丙基氨基,3-硫代吗啉基丙基氨基,3-(4-N-甲基哌嗪基)丙基氨基,N-甲基哌啶-4-氨基,N-乙基哌啶-4-氨基,N-异丙基哌啶-4-氨基,(4)2-N,N-二甲基氨基乙氧基,2-N,N-二乙基氨基乙氧基,2-N,N-二异丙基氨基乙氧基,2-(N-甲基哌嗪基)乙氧基,2-(N-乙酰基哌嗪基)乙氧基,2-吗啡啉基乙氧基,2-硫代吗啉基乙氧基,2-哌啶基乙氧基,3-N,N-二甲基氨基丙氧基,3-N,N-二乙基氨基丙氧基,3-N,N-二异丙基氨基丙氧基,3-(N-甲基哌嗪基)丙氧基,3-(N-乙酰基哌嗪基)丙氧基,3-吗啡啉基丙氧基,3-硫代吗啉基丙氧基,3-哌啶基丙氧基,2-吡啶基甲氧基,3-吡啶基甲氧基,4-吡啶基甲氧基,苯基甲氧基,单卤素取代苯基甲氧基,偕二卤素取代苯基甲氧基,杂二卤素取代苯基甲氧基,(5)哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,吗啡啉基,3,5-二甲基吗啡啉基,硫代吗啉基,四氢吡咯基,3-N,N-二甲基四氢吡咯基,3-N,N-二乙基四氢吡咯基,N-甲基哌嗪基,N-乙基哌嗪基,N-异丙基哌嗪基, N-乙酰基哌嗪基,N-叔丁氧甲酰基哌嗪基,N-甲磺酰基哌嗪基,N-(2-羟基乙基)哌嗪基,N-(2-氰基乙基)哌嗪基,N-(3-羟基丙基)哌嗪基,N-(2-N,N-二甲基乙基)哌嗪基,N-(2-N,N-二乙基乙基)哌嗪基,N-(3-N,N-二甲基丙基)哌嗪基,N-(3-N,N-二乙基丙基)哌嗪基,2-氧代-哌嗪基,2-氧代-哌嗪-4-基,咪唑基,4-甲基咪唑基,(6)4-(N-甲基哌嗪基)哌啶基,4-(N-乙基哌嗪基)哌啶基,4-(N-异丙基哌嗪基)哌啶基,4-(N-乙酰基哌嗪基)哌啶基,4-(N-叔丁氧甲酰基哌嗪基)哌啶基,4-(N-甲磺酰基哌嗪基)哌啶基,4-(N-(2-羟基乙基)哌嗪基)哌啶基,4-(N-(2-氰基乙基)哌嗪基)哌啶基,4-(N-(3-羟基丙基)哌嗪基)哌啶基,4-(N-(2-N,N-二甲基乙基)哌嗪基)哌啶基,4-(N-(2-N,N-二乙基乙基)哌嗪基)哌啶基,4-(N-(3-N,N-二甲基丙基)哌嗪基)哌啶基,4-(N-(3-N,N-二乙基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基四氢吡咯基)哌啶基,N-(N-甲基-4-哌啶基)哌嗪基,N-(N-乙基-4-哌啶基)哌嗪基,(7)羟基磺酰基,氨基磺酰基,甲胺基磺酰基,乙胺基磺酰基,丙胺基磺酰基,异丙胺基磺酰基,环丙基胺基磺酰基,环丁基胺基磺酰基,环戊基胺基磺酰基,哌啶基-1-磺酰基,4-羟基哌啶基-1-磺酰基,4-N,N-二甲基哌啶基-1-磺酰基,4-N,N-二乙基哌啶基-1-磺酰基,四氢吡咯基-1-磺酰基,3-N,N-二甲基四氢吡咯基-1-磺酰基,3-N,N-二乙基四氢吡咯基-1-磺酰基,N-甲基哌嗪基-1-磺酰基,N-乙基哌嗪基-1-磺酰基,N-乙酰基哌嗪基-1-磺酰基,N-叔丁氧甲酰基哌嗪基-1-磺酰基,N-(2-羟基乙基)哌嗪基-1-磺酰基,N-(2-氰基乙基)哌嗪基-1-磺酰基,N-(2-N,N-二甲基乙基)哌嗪基-1-磺酰基,N-(2-N,N-二乙基乙基)哌嗪基-1-磺酰基,N-(3-羟基丙基)哌嗪基-1-磺酰基,N-(3-N,N-二甲基丙基)哌嗪基-1-磺酰基,N-(3-N,N-二乙基丙基)哌嗪基-1-磺酰基,吗啡啉基-1-磺酰基,3,5-二甲基吗啡啉基-1-磺酰基,4-(N-甲基-1-哌嗪基)哌啶基-1-磺酰基,4-(N-乙基-1-哌嗪基)哌啶基-1-磺酰基,4-(N-乙酰基-1-哌嗪基)哌啶基-1-磺酰基,N-(N-甲基-4-哌啶基)哌嗪基-1-磺酰基,(8)氨基甲酰基,甲胺基甲酰基,乙胺基甲酰基,丙胺基甲酰基,异丙胺基甲酰基,环丙基胺基甲酰基,环丁基胺基甲酰基,环戊基胺基甲酰基,哌啶基-1-甲酰基,4-羟基哌啶基-1-甲酰基,4-N,N-二甲基哌啶基-1-甲酰基,4-N,N-二乙基哌啶基-1-甲酰基,四氢吡咯基-1-甲酰基,3-N,N-二甲基四氢吡咯基-1-甲酰基,3-N,N-二乙基四氢吡咯基-1-甲酰基,N-甲基哌嗪基-1-甲酰基,N-乙基哌嗪基-1-甲酰基,N-乙酰基哌嗪基-1-甲酰基,N-叔丁氧甲酰基哌嗪基-1-甲酰基,N-(2-羟基乙基)哌嗪基-1-甲酰基,N-(2-氰基乙基)哌嗪基-1-甲酰基,N-(2-N,N-二甲基乙基)哌嗪基-1-甲酰基,N-(2-N,N-二乙基乙基)哌嗪基-1-甲酰基,N-(3-羟基丙基)哌嗪基-1-甲酰基,N-(3-N,N-二甲基丙基)哌嗪基-1-甲酰基,N-(3-N,N-二乙基丙基)哌嗪基-1-甲酰基,吗啡啉基-1-甲酰基,3,5-二甲基吗啡啉基-1-甲酰基,4-(N-甲基-1-哌嗪基)哌啶基-1-甲酰基,4-(N-乙基-1-哌嗪基)哌啶基-1-甲酰基,4-(N-乙酰基-1-哌嗪基)哌啶基-1-甲酰基,N-(N-甲基-4-哌啶基)哌嗪基-1-甲酰基,(9)羟基甲酰基,甲氧基甲酰基,乙氧基甲酰基,丙氧基甲酰基,异丙氧基甲酰基,正丁氧基甲酰基,异丁氧基甲酰基,叔丁氧基甲酰基,(10)氨基甲酰胺基,甲胺基甲酰胺基,乙胺基甲酰胺基,丙胺基甲酰胺基,异丙胺基甲酰胺基,环丙基胺基甲酰胺基,环丁基胺基甲酰胺基,环戊基胺基甲酰胺基,哌啶基-1-甲酰胺基,4-羟基哌啶基-1-甲酰胺基,4-N,N-二甲基哌啶基-1-甲酰胺基,4-N,N-二乙基哌啶基-1-甲酰胺基,四氢吡咯基-1-甲酰胺基,3-N,N-二甲基四氢吡咯基-1-甲酰胺基,3-N,N-二乙基四氢吡咯基-1-甲酰胺基,N-甲基哌嗪基-1-甲酰胺基,N-乙基哌嗪基-1-甲酰胺基,N-乙酰基哌嗪基-1-甲酰胺基,N-叔丁氧甲酰基哌嗪基-1-甲酰胺基,N-(2-羟基乙基)哌嗪基-1-甲酰胺基,N-(2-氰基乙基)哌嗪基-1-甲酰胺基,N-(2-N,N-二甲基乙基)哌嗪基-1-甲酰胺基,N-(2-N,N-二乙基乙基)哌嗪基-1-甲酰胺基,N-(3-羟基丙基)哌嗪基-1-甲酰胺基,N-(3-N,N-二甲基丙基)哌嗪基-1-甲酰胺基,N-(3-N,N-二乙基丙基)哌嗪基-1-甲酰胺基,吗啡啉基-1-甲酰胺基,3,5-二甲基吗 啡啉基-1-甲酰胺基,4-(N-甲基-1-哌嗪基)哌啶基-1-甲酰胺基,4-(N-乙基-1-哌嗪基)哌啶基-1-甲酰胺基,4-(N-乙酰基-1-哌嗪基)哌啶基-1-甲酰胺基,N-(N-甲基-4-哌啶基)哌嗪基-1-甲酰胺基;或(11)氨基乙酰胺基,N-叔丁氧甲酰基乙酰胺基,N-乙酰基氨基乙酰胺基,丙烯酰胺基,环丙酰胺基,氯乙酰胺基,溴乙酰胺基,哌啶基乙酰胺基,4-羟基哌啶基乙酰胺基,4-N,N-二甲基哌啶基乙酰胺基,4-N,N-二乙基哌啶基乙酰胺基,四氢吡咯基乙酰胺基,3-N,N-二甲基四氢吡咯基乙酰胺基,3-N,N-二乙基四氢吡咯基乙酰胺基,N-甲基哌嗪基乙酰胺基,N-乙基哌嗪基乙酰胺基,N-乙酰基哌嗪基乙酰胺基,N-叔丁氧甲酰基哌嗪基乙酰胺基,N-(2-羟基乙基)哌嗪基乙酰胺基,N-(2-氰基乙基)哌嗪基乙酰胺基,N-(2-N,N-二甲基乙基)哌嗪基乙酰胺基,N-(2-N,N-二乙基乙基)哌嗪基乙酰胺基,N-(3-羟基丙基)哌嗪基乙酰胺基,N-(3-N,N-二甲基丙基)哌嗪基乙酰胺基,N-(3-N,N-二乙基丙基)哌嗪基乙酰胺基,吗啡啉基乙酰胺基,3,5-二甲基吗啡啉基乙酰胺基,4-(N-甲基-1-哌嗪基)哌啶基乙酰胺基,4-(N-乙基-1-哌嗪基)哌啶基乙酰胺基,4-(N-乙酰基-1-哌嗪基)哌啶基乙酰胺基,N-(N-甲基-4-哌啶基)哌嗪基乙酰胺基,4-(四氢吡咯-1-基)哌啶基乙酰胺基;2-甲基氨基乙酰胺基,2-(1-甲基乙基)氨基乙酰胺基;N-苄氧基甲酰基-2甲基氨基乙酰胺基;(12)Z2与Z3可以形成含氧的取代或未取代的五元环或六元环;取代基可以选自与Z1相同的上述取代基,(13)Z2与Z3可以形成含氮的取代或未取代的五元环或六元环;取代基可以选自与Z1相同的上述取代基,优选R11选自:1)C1-C6烷基,其任选地被卤素、硝基、氰基取代;C1-C6含氧烷基;C3-C7环烷基,其任选地被卤素、硝基、氰基取代;C6-10芳基,其任选地被卤素、硝基、氨基、羟基、氰基取代;2)2-N,N-二甲基氨基乙基,2-羟基乙基,2-N,N-二乙基氨基乙基,2-N,N-二异丙基氨基乙基,2-吗啡啉基乙基,2-硫代吗啉基乙基,2-(4-N-甲基哌嗪基)乙基,3-N,N-二甲基氨基丙基,3-N,N-二乙基氨基丙基,3-N,N-二异丙基氨基丙基,3-吗啡啉基丙基,3-硫代吗啉基丙基,3-(4-N-甲基哌嗪)基丙基,4-N,N-二甲基氨基环己基,4-N,N-二乙基氨基环己基,N-甲基-4-哌啶基,N-乙基-4-哌啶基,N-异丙基-4-哌啶基,1,3-二甲基-5-吡唑基,1-甲基-4-吡唑基,3-甲基-5-异噁唑啉基,1-(N-甲基-4-哌啶基)-4-吡唑基,1-(N-叔丁氧甲酰基-4-哌啶基)-4-吡唑基;优选R11中的Z3选自氨基、氨基磺酰基、甲胺基磺酰基、环丙基胺基磺酰基、哌啶基-1-磺酰基、4-羟基哌啶基-1-磺酰基、4-N,N-二甲基哌啶基-1-磺酰基、四氢吡咯基-1-磺酰基、3-N,N-二甲基四氢吡咯基-1-磺酰基、N-甲基哌嗪基-1-磺酰基、N-乙基哌嗪基-1-磺酰基、吗啡啉基-1-磺酰基、甲基磺酰胺基,乙基磺酰胺基,异丙基磺酰胺基,乙烯基磺酰胺基,甲酸基、氨基甲酰基、甲胺基甲酰基、乙胺基甲酰基、异丙胺基甲酰基、环丙基胺基甲酰基、哌啶基-1-甲酰基、4-羟基哌啶基-1-甲酰基、4-N,N-二甲基哌啶基-1-甲酰基、四氢吡咯基-1-甲酰基、3-N,N-二甲基四氢吡咯基-1-甲酰基、N-甲基哌嗪基-1-甲酰基、N-乙基哌嗪基-1-甲酰基、N-乙酰基哌嗪基-1-甲酰基、吗啡啉基-1-甲酰基、4-(N-甲基-1-哌嗪基)哌啶基-1-甲酰基、4-(N-乙基-1-哌嗪基)哌 啶基-1-甲酰基、4-(N-乙酰基-1-哌嗪基)哌啶基-1-甲酰基、N-(N-甲基-4-哌啶基)哌嗪基-1-甲酰基,氯乙酰胺基,溴乙酰胺基,丙烯酰胺基;R21选自:1)氢,卤素,硝基,氨基,氰基;2)C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;-O-C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C1-C6含氧烷基;3)甲硫基,乙硫基,异丙硫基,甲亚磺酰基,乙亚磺酰基,异丙亚磺酰基,甲磺酰基,乙磺酰基,异丙磺酰基,氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙氨基磺酰基,羟基甲酰基,甲氧基甲酰基,乙氧基甲酰基,丙氧基甲酰基,异丙氧基甲酰基,正丁氧基甲酰基,异丁氧基甲酰基,叔丁氧基甲酰基,氨基甲酰基,甲胺基甲酰基,乙胺基甲酰基,丙胺基甲酰基,异丙胺基甲酰基,环丙基胺基甲酰基,环丁基胺基甲酰基,环戊基胺基甲酰基,乙酰胺基,丙酰胺基,正丁基酰胺基,异丁基酰胺基,环丙基甲酰胺基,环丁基甲酰胺基,环戊基甲酰胺基,甲磺酰胺基,乙磺酰胺基,丙磺酰胺基,异丙磺酰胺基,二甲基次磷酰基,二乙基次磷酰基,二异丙基次磷酰基;优选R21选自:氢,卤素,硝基,氨基,氰基;C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;-O-C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C1-C6含氧烷基;R31选自:氢;C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C3-C7环烷基,其任选地被卤素、硝基、氨基、氰基取代;优选R31选自:氢;C1-C6烷基;C3-C7环烷基;R41选自:氢;C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C3-C7环烷基,其任选地被卤素、硝基、氨基、氰基取代;优选R41选自:氢;C1-C6烷基;C3-C7环烷基;R51选自:1)氢,卤素,硝基,氨基,氰基;2)C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;-O-C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C1-C6含氧烷基;3)甲硫基,乙硫基,异丙硫基,甲亚磺酰基,乙亚磺酰基,异丙亚磺酰基,甲磺酰基,乙磺酰基,异丙磺酰基,氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙氨基磺酰基,羟基甲酰基,甲氧基甲酰基,乙氧基甲酰基,丙氧基甲酰基,异丙氧基甲酰基,正丁氧基甲酰基,异丁氧基甲酰基,叔丁氧基甲酰基,氨基甲酰基,甲胺基甲酰基,乙胺基甲酰基,丙胺基甲酰基,异丙胺基甲酰基,环丙基胺基甲酰基,环丁基胺基甲酰基,环戊基胺基甲酰基,乙酰胺基,丙酰胺基,正丁基酰胺基,异丁基酰胺基,环丙基甲酰胺基,环丁基甲酰胺基,环戊基甲酰胺基,甲磺酰胺基,乙磺酰胺基,丙磺酰胺基,异丙磺酰胺基,二甲基次磷酰基,二乙基次磷酰基,二异丙基次磷酰基;优选R51选自:氢,卤素,硝基,氨基,氰基;C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;-O-C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C1-C6含氧烷基;或上述化合物的立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物;优选药学上可接受的盐为无机酸盐或有机酸盐,其中,所述无机酸盐为盐酸盐、氢溴酸盐、氢碘酸盐、硝酸盐、碳酸氢盐和碳酸盐、硫酸盐或磷酸盐,所述有机酸盐为甲酸盐、乙酸盐、丙酸盐、苯甲酸盐、马来酸盐、富马酸盐、琥珀酸盐、酒石酸盐、柠檬酸盐、抗坏血酸盐、α-酮戊二酸盐、α-甘油磷酸盐、烷基磺酸盐或芳基磺酸盐;优选地,所述烷基磺酸盐为甲基磺酸盐或乙 基磺酸盐;所述芳基磺酸盐为苯磺酸盐或对甲苯磺酸盐。
- 根据权利要求1的化合物,其为以下:n4选自0,1或2;优选n4选自0,1;R14选自:1)包含选自N、O和S的一个或多个杂原子的五元杂环或六元杂环,所述五元杂环或六元杂环任选地被C1-C6烷基、C1-C6烷氧基、羟基、氨基、烷基氨基、二烷基氨基、C1-C6酰基、氰基、任选被C1-C6烷基、-O-C1-C6烷基、羟基、羟基C1-C6烷基、C1-C6酰基、烷基氨基、二烷基氨基取代的杂环基取代,包括但不限于:4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(N-甲基哌嗪基)哌啶基,4-(N-乙基哌嗪基)哌啶基,4-(N-异丙基哌嗪基)哌啶基,4-(N-乙酰基哌嗪基)哌啶基,4-(N-叔丁氧甲酰基哌嗪基)哌啶基,4-(N-甲磺酰基哌嗪基)哌啶基,4-(N-(2-羟基乙基)哌嗪基)哌啶基,4-(N-(2-氰基乙基)哌嗪基)哌啶基,4-(N-(3-羟基丙基)哌嗪基)哌啶基,4-(N-(2-N,N-二甲基乙基)哌嗪基)哌啶基,4-(N-(2-N,N-二乙基乙基)哌嗪基)哌啶基,4-(N-(3-N,N-二甲基丙基)哌嗪基)哌啶基,4-(N-(3-N,N-二乙基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基四氢吡咯基)哌啶基;2)氨基,环丙基氨基,环丁基氨基,环戊基氨基,环己基氨基,N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基,2-N,N-二甲基氨基乙基氨基,2-羟基乙基氨基,2-吗啡啉基乙基氨基,2-(4-N-甲基哌嗪基)乙基氨基,3-N,N-二甲基氨基丙基氨基,3-N,N-二乙基氨基丙基氨基,3-N,N-二异丙基氨基丙基氨基,3-羟基丙基氨基,3-吗啡啉基丙基氨基,3-(4-N-甲基哌嗪基)丙基氨基,N-甲基哌啶-4-氨基,N-乙基哌啶-4-氨基,N-异丙基哌啶-4-氨基,N-乙酰基哌啶-4-氨基;N-甲基哌嗪基,N-乙基哌嗪基,N-异丙基哌嗪基,N-乙酰基哌嗪基,N-叔丁氧甲酰基哌嗪基,N-甲磺酰基哌嗪基,N-(2-羟基乙基)哌嗪基,N-(2-氰基乙基)哌嗪基,N-(3-羟基丙基)哌嗪基,N-(2-N,N-二甲基乙基)哌嗪基,N-(2-N,N-二乙基乙基)哌嗪基,N-(3-N,N-二甲基丙基)哌嗪基,N-(3-N,N-二乙基丙基)哌嗪基,2-氧代-哌嗪-4-基,N-(N-甲基-4-哌啶基)哌嗪基,N-(N-乙基-4-哌啶基)哌嗪基,N-(N-乙酰基-4-哌啶基)哌嗪基;吗啡啉基,3,5-二甲基吗啡啉基,硫代吗啉基,四氢吡咯基,3-N,N-二甲基四氢吡咯基,3-N,N-二乙基四氢吡咯基;3)C1-C6烷基,其任选地被卤素、硝基、氰基取代;4)C3-C7环烷基,其任选地被卤素、硝基、氰基取代;5)-O-C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;6)-O-C3-C7环烷基,其任选地被卤素、硝基、氨基、氰基取代;7)C6-C10芳基,其任选地被卤素、硝基、氨基、氰基取代;-O-C6-C10芳基,其任选地被卤素、硝基、氨基、氰基取代;8)C2-C6烯基;9)羟基,2-N,N-二甲基氨基乙氧基,2-N,N-二乙基氨基乙氧基,2-N,N-二异丙基氨基乙氧基,2-(N-甲基哌嗪基)乙氧基,2-(N-乙酰基哌嗪基)乙氧基,2-吗啡啉基乙氧基,2-硫代吗啉基乙氧基,2-哌啶基乙氧基,3-N,N-二甲基氨基丙氧基,3-N,N-二乙基氨基丙氧基,3-N,N- 二异丙基氨基丙氧基,3-(N-甲基哌嗪基)丙氧基,3-(N-乙酰基哌嗪基)丙氧基,3-吗啡啉基丙氧基,3-硫代吗啉基丙氧基,3-哌啶基丙氧基,2-吡啶基甲氧基,3-吡啶基甲氧基,4-吡啶基甲氧基,苯基甲氧基,单卤素取代苯基甲氧基,偕二卤素取代苯基甲氧基,杂二卤素取代苯基甲氧基;优选R14选自:1)C1-C6烷基,C3-C7环烷基;2)氨基,环丙基氨基,环戊基氨基,环己基氨基,N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基,2-N,N-二甲基氨基乙基氨基,2-羟基乙基氨基,2-吗啡啉基乙基氨基,2-(4-N-甲基哌嗪基)乙基氨基,N-甲基哌啶-4-氨基,N-乙基哌啶-4-氨基,N-异丙基哌啶-4-氨基,N-乙酰基哌啶-4-氨基;3)羟基,2-N,N-二甲基氨基乙氧基,2-N,N-二乙基氨基乙氧基,2-N,N-二异丙基氨基乙氧基,2-(N-甲基哌嗪基)乙氧基,2-(N-乙酰基哌嗪基)乙氧基,2-吗啡啉基乙氧基,2-硫代吗啉基乙氧基,2-哌啶基乙氧基,3-N,N-二甲基氨基丙氧基,3-N,N-二乙基氨基丙氧基,3-N,N-二异丙基氨基丙氧基,3-(N-甲基哌嗪基)丙氧基,3-(N-乙酰基哌嗪基)丙氧基,3-吗啡啉基丙氧基,3-硫代吗啉基丙氧基,3-哌啶基丙氧基,2-吡啶基甲氧基,3-吡啶基甲氧基,4-吡啶基甲氧基;4)哌啶基,4-N,N-二甲基氨基哌啶基,4-羟基哌啶基,4-(N-甲基哌嗪基)哌啶基,4-(N-乙基哌嗪基)哌啶基,4-(N-乙酰基哌嗪基)哌啶基,4-(N-叔丁氧甲酰基哌嗪基)哌啶基,4-(N-甲磺酰基哌嗪基)哌啶基,4-(N-(2-羟基乙基)哌嗪基)哌啶基,4-(N-(2-氰基乙基)哌嗪基)哌啶基,4-(N-(3-羟基丙基)哌嗪基)哌啶基,4-(N-(2-N,N-二甲基乙基)哌嗪基)哌啶基,4-(N-(2-N,N-二乙基乙基)哌嗪基)哌啶基,4-(N-(3-N,N-二甲基丙基)哌嗪基)哌啶基,4-(N-(3-N,N-二乙基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基四氢吡咯基)哌啶基;5)N-甲基哌嗪基,N-乙基哌嗪基,N-异丙基哌嗪基,N-乙酰基哌嗪基,N-(2-羟基乙基)哌嗪基,N-(2-氰基乙基)哌嗪基,N-(3-羟基丙基)哌嗪基,N-(2-N,N-二甲基乙基)哌嗪基,N-(2-N,N-二乙基乙基)哌嗪基,N-(3-N,N-二甲基丙基)哌嗪基,N-(3-N,N-二乙基丙基)哌嗪基,2-氧代-哌嗪-4-基,N-(N-甲基-4-哌啶基)哌嗪基,N-(N-乙基-4-哌啶基)哌嗪基,N-(N-乙酰基-4-哌啶基)哌嗪基;6)吗啡啉基,3,5-二甲基吗啡啉基,硫代吗啉基,四氢吡咯基,3-N,N-二甲基四氢吡咯基,3-N,N-二乙基四氢吡咯基;更优选R14选自:1)甲基,乙基,异丙基,三氟甲基;2)氨基,环丙基氨基,N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基;3)羟基;4)哌啶基,4-N,N-二甲基氨基哌啶基,4-羟基哌啶基,4-(N-甲基哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基四氢吡咯基)哌啶基;5)N-甲基哌嗪基,N-乙基哌嗪基,N-异丙基哌嗪基,N-乙酰基哌嗪基,N-(2-羟基乙基)哌嗪基,N-(2-氰基乙基)哌嗪基,N-(3-羟基丙基)哌嗪基,N-(2-N,N-二甲基乙基)哌嗪基,N-(2-N,N-二乙基乙基)哌嗪基,N-(3-N,N-二甲基丙基)哌嗪基,N-(3-N,N-二乙基丙基)哌嗪基,2-氧代-哌嗪-4-基,N-(N-甲基-4-哌啶基)哌嗪基,N-(N-乙基-4-哌啶基)哌嗪基,N-(N-乙酰基-4-哌啶基)哌嗪基;6)吗啡啉基,3,5-二甲基吗啡啉基,硫代吗啉基,四氢吡咯基,3-N,N-二甲基四氢吡咯基,3-N,N-二乙基四氢吡咯基;R24选自:1)氢,卤素,硝基,氨基,氰基;2)C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;-O-C1-C6烷基,其任选地被卤 素、硝基、氨基、氰基取代;C1-C6含氧烷基;3)甲硫基,乙硫基,异丙硫基,甲亚磺酰基,乙亚磺酰基,异丙亚磺酰基,甲磺酰基,乙磺酰基,异丙磺酰基,氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙氨基磺酰基,羟基甲酰基,甲氧基甲酰基,乙氧基甲酰基,丙氧基甲酰基,异丙氧基甲酰基,正丁氧基甲酰基,异丁氧基甲酰基,叔丁氧基甲酰基,氨基甲酰基,甲胺基甲酰基,乙胺基甲酰基,丙胺基甲酰基,异丙胺基甲酰基,环丙基胺基甲酰基,环丁基胺基甲酰基,环戊基胺基甲酰基,乙酰胺基,丙酰胺基,正丁基酰胺基,异丁基酰胺基,环丙基甲酰胺基,环丁基甲酰胺基,环戊基甲酰胺基,甲磺酰胺基,乙磺酰胺基,丙磺酰胺基,异丙磺酰胺基,二甲基次磷酰基,二乙基次磷酰基,二异丙基次磷酰基;优选R24选自:氢、卤素、硝基、氨基、氰基、C1-C6烷基,所述C1-C6烷基任选地被卤素、硝基、氨基、氰基取代;-O-C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;更优选R24选自:氢、卤素、氰基、C1-C6烷基,所述C1-C6烷基任选地被卤素、硝基、氨基、氰基取代;R34选自:氢;C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C3-C7环烷基,其任选地被卤素、硝基、氨基、氰基取代;优选R34选自:氢;C1-C6烷基;C3-C7环烷基;更优选R34选自:氢、甲基、乙基、异丙基、环丙基或环戊基;R44选自:氢;C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C3-C7环烷基,其任选地被卤素、硝基、氨基、氰基取代;优选R44选自:氢;C1-C6烷基;C3-C7环烷基;更优选R44选自:氢、甲基、乙基、异丙基、环丙基或环戊基;或上述化合物的立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物;优选药学上可接受的盐为无机酸盐或有机酸盐,其中,所述无机酸盐为盐酸盐、氢溴酸盐、氢碘酸盐、硝酸盐、碳酸氢盐和碳酸盐、硫酸盐或磷酸盐,所述有机酸盐为甲酸盐、乙酸盐、丙酸盐、苯甲酸盐、马来酸盐、富马酸盐、琥珀酸盐、酒石酸盐、柠檬酸盐、抗坏血酸盐、α-酮戊二酸盐、α-甘油磷酸盐、烷基磺酸盐或芳基磺酸盐;优选地,所述烷基磺酸盐为甲基磺酸盐或乙基磺酸盐;所述芳基磺酸盐为苯磺酸盐或对甲苯磺酸盐。
- 根据权利要求1的化合物,其为以下:m5选自0,1,2,3或4;优选m5选自0,1,2,3;更优选m5选自0,1,2;n5选自0,1或2;优选n5选自0,1;更优选n5为0;R15、R25独立地选自:1)氢;C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C3-C7环烷基,其任选地被卤素、硝基、氨基、氰基取代;C1-C6含氧烷基;2)-SO2C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;-SO2C2-C6烯基,其任选地被卤素、硝基、氨基、氰基取代;-COC1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;-COC2-C6烯基,其任选地被卤素、硝基、氨基、氰基取代;优选R15选自:氢;C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;-SO2C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;-SO2C2-C6烯基,其任选地被卤素、硝基、氨基、氰基取代;-COC1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;-COC2-C6烯基,其任选地被卤素、硝基、氨基、氰基取代;优选R25选自:氢;C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;更优选R25为氢;或者,R15和R25以及它们所连接的N原子一起形成包含选自N、O和S的一个或多个杂原子的六元杂环,所述六元杂环任选地被C1-C6烷基、羟基、氨基取代;优选R15和R25以及它们所连接的N原子一起形成包含选自N、O和S的一个或多个杂原子的六元杂环,所述六元杂环任选地被C1-C6烷基、羟基、氨基取代;更优选R15和R25以及它们所连接的N原子一起形成哌啶环、哌嗪环,所述哌啶环、哌嗪环任选地被C1-C6烷基、羟基取代;R35选自:1)氢,卤素,硝基,氨基,氰基;2)C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;-O-C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C1-C6含氧烷基;3)甲硫基,乙硫基,异丙硫基,甲亚磺酰基,乙亚磺酰基,异丙亚磺酰基,甲磺酰基,乙磺酰基,异丙磺酰基,氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙氨基磺酰基,羟基甲酰基,甲氧基甲酰基,乙氧基甲酰基,丙氧基甲酰基,异丙氧基甲酰基,正丁氧基甲酰基,异丁氧基甲酰基,叔丁氧基甲酰基,氨基甲酰基,甲胺基甲酰基,乙胺基甲酰基,丙胺基甲酰基,异丙胺基甲酰基,环丙基胺基甲酰基,环丁基胺基甲酰基,环戊基胺基甲酰基,乙酰胺基,丙酰胺基,正丁基酰胺基,异丁基酰胺基,环丙基甲酰胺基,环丁基甲酰胺基,环戊基甲酰胺基,甲磺酰胺基,乙磺酰胺基,丙磺酰胺基,异丙磺酰胺基,二甲基次磷酰基,二乙基次磷酰基,二异丙基次磷酰基;优选R35选自:氢、卤素、硝基、氨基、氰基、C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C3-C7环烷基,其任选地被卤素、硝基、氨基、氰基取代;更优选R35选自:氢、卤素、硝基、氨基、氰基、C1-C6烷基;R45选自:氢;C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C3-C7环烷基,其任选地被卤素、硝基、氨基、氰基取代;优选R45选自:氢;C1-C6烷基;C3-C7环烷基;更优选R45选自:氢、甲基、乙基、异丙基、环丙基或环戊基;R55选自:氢;C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C3-C7环烷基,其任选地被卤素、硝基、氨基、氰基取代;优选R55选自:氢;C1-C6烷基;C3-C7环烷基;更优选R55选自:氢、甲基、乙基、异丙基、环丙基或环戊基;R65选自:1)氢,卤素,硝基,氨基,氰基;2)C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;-O-C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C1-C6含氧烷基;3)甲硫基,乙硫基,异丙硫基,甲亚磺酰基,乙亚磺酰基,异丙亚磺酰基,甲磺酰基,乙磺酰基,异丙磺酰基,氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙氨基磺酰基,羟基甲酰基,甲氧基甲酰基,乙氧基甲酰基,丙氧基甲酰基,异丙氧基甲酰基,正丁氧基甲酰基,异丁氧基甲酰基,叔丁氧基甲酰基,氨基甲酰基,甲胺基甲酰基,乙胺基甲酰基,丙胺基甲酰基,异丙胺基甲酰基,环丙基胺基甲酰基,环丁基胺基甲酰基,环戊基胺基甲酰基,乙酰胺基,丙酰胺基,正丁基酰胺基,异丁基酰胺基,环丙基甲酰胺基,环丁基甲酰胺基,环戊基甲酰胺基,甲磺酰胺基,乙磺酰胺基,丙磺酰胺基,异丙磺酰胺基,二甲基次磷酰基,二乙基次磷酰基,二异丙基次磷酰基;优选R65选自:氢、卤素、硝基、氨基、氰基、C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C3-C7环烷基,其任选地被卤素、硝基、氨基、氰基取代;更优选R65选自:氢、卤素、硝基、氨基、氰基、C1-C6烷基;或上述化合物的立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物;优选药学上可接受的盐为无机酸盐或有机酸盐,其中,所述无机酸盐为盐酸盐、氢溴酸盐、氢碘酸盐、硝酸盐、碳酸氢盐和碳酸盐、硫酸盐或磷酸盐,所述有机酸盐为甲酸盐、乙酸盐、丙酸盐、苯甲酸盐、马来酸盐、富马酸盐、琥珀酸盐、酒石酸盐、柠檬酸盐、抗坏血酸盐、α-酮戊二酸盐、α-甘油磷酸盐、烷基磺酸盐或芳基磺酸盐;优选地,所述烷基磺酸盐为甲基磺酸盐或乙基磺酸盐;所述芳基磺酸盐为苯磺酸盐或对甲苯磺酸盐。
- 根据权利要求1的化合物,其为以下:n6选自0,1或2;优选n6选自0,1;更优选n6为0;R16选自:1)氢;C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C3-C7环烷基,其任选地被卤素、硝基、氨基、氰基取代;C1-C6含氧烷基;2)-SO2C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;-SO2C2-C6烯基,其任选地被卤素、硝基、氨基、氰基取代;-COC1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;-COC2-C6烯基,其任选地被卤素、硝基、氨基、氰基取代;3)哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(N-甲基哌嗪基)哌啶基,4-(N-乙基哌嗪基)哌啶基,4-(N-异丙基哌嗪基)哌啶基,4-(N-乙酰基哌嗪基)哌啶基,4-(N-叔丁氧甲酰基哌嗪基)哌啶基,4-(N-甲磺酰基哌嗪基)哌啶基,4-(N-(2-羟基乙基)哌嗪基)哌啶基,4-(N-(2-氰基乙基)哌嗪基)哌啶基,4-(N-(3-羟基丙基)哌嗪基)哌啶基,4-(N-(2-N,N-二甲基乙基)哌嗪基)哌啶基,4-(N-(2-N,N-二乙基乙 基)哌嗪基)哌啶基,4-(N-(3-N,N-二甲基丙基)哌嗪基)哌啶基,4-(N-(3-N,N-二乙基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基四氢吡咯基)哌啶基;优选R16选自:氢;C1-C6烷基;C3-C7环烷基;-SO2C1-C6烷基;-SO2C2-C6烯基;-COC1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;-COC2-C6烯基,其任选地被卤素、硝基、氨基、氰基取代;更优选R16选自氢;氢;甲基、乙基、异丙基、环丙基;甲磺酰基、乙磺酰基、异丙磺酰基、乙烯基磺酰基;乙酰基、氯乙酰基、溴乙酰基、丙烯酰基、4-N,N-二甲基氨基-2-丁烯酰基,4-四氢吡咯基-2-丁烯酰基;R26选自:1)氢,卤素,硝基,氨基,氰基;2)C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;-O-C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C1-C6含氧烷基;3)甲硫基,乙硫基,异丙硫基,甲亚磺酰基,乙亚磺酰基,异丙亚磺酰基,甲磺酰基,乙磺酰基,异丙磺酰基,氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙氨基磺酰基,羟基甲酰基,甲氧基甲酰基,乙氧基甲酰基,丙氧基甲酰基,异丙氧基甲酰基,正丁氧基甲酰基,异丁氧基甲酰基,叔丁氧基甲酰基,氨基甲酰基,甲胺基甲酰基,乙胺基甲酰基,丙胺基甲酰基,异丙胺基甲酰基,环丙基胺基甲酰基,环丁基胺基甲酰基,环戊基胺基甲酰基,乙酰胺基,丙酰胺基,正丁基酰胺基,异丁基酰胺基,环丙基甲酰胺基,环丁基甲酰胺基,环戊基甲酰胺基,甲磺酰胺基,乙磺酰胺基,丙磺酰胺基,异丙磺酰胺基,二甲基次磷酰基,二乙基次磷酰基,二异丙基次磷酰基;优选R26选自:氢、卤素、硝基、氨基、氰基、C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C3-C7环烷基,其任选地被卤素、硝基、氨基、氰基取代;更优选R26选自:氢、卤素、硝基、氨基、氰基、C1-C6烷基;R36选自:氢;C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C3-C7环烷基,其任选地被卤素、硝基、氨基、氰基取代;优选R36选自:氢;C1-C6烷基;C3-C7环烷基;R46选自:氢;C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C3-C7环烷基,其任选地被卤素、硝基、氨基、氰基取代;优选R46选自:氢;C1-C6烷基;C3-C7环烷基;或上述化合物的立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物;优选药学上可接受的盐为无机酸盐或有机酸盐,其中,所述无机酸盐为盐酸盐、氢溴酸盐、氢碘酸盐、硝酸盐、碳酸氢盐和碳酸盐、硫酸盐或磷酸盐,所述有机酸盐为甲酸盐、乙酸盐、丙酸盐、苯甲酸盐、马来酸盐、富马酸盐、琥珀酸盐、酒石酸盐、柠檬酸盐、抗坏血酸盐、α-酮戊二酸盐、α-甘油磷酸盐、烷基磺酸盐或芳基磺酸盐;优选地,所述烷基磺酸盐为甲基磺酸盐或乙基磺酸盐;所述芳基磺酸盐为苯磺酸盐或对甲苯磺酸盐。
- 根据权利要求1的化合物,其为以下:n7选自0,1或2;优选n7选自0,1;更优选n7为0;R17选自:1)氢;C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C3-C7环烷基,其任选地被卤素、硝基、氨基、氰基取代;C1-C6含氧烷基;2)-SO2C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;-SO2C2-C6烯基,其任选地被卤素、硝基、氨基、氰基取代;-COC1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;-COC2-C6烯基,其任选地被卤素、硝基、氨基、氰基取代;3)哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(N-甲基哌嗪基)哌啶基,4-(N-乙基哌嗪基)哌啶基,4-(N-异丙基哌嗪基)哌啶基,4-(N-乙酰基哌嗪基)哌啶基,4-(N-叔丁氧甲酰基哌嗪基)哌啶基,4-(N-甲磺酰基哌嗪基)哌啶基,4-(N-(2-羟基乙基)哌嗪基)哌啶基,4-(N-(2-氰基乙基)哌嗪基)哌啶基,4-(N-(3-羟基丙基)哌嗪基)哌啶基,4-(N-(2-N,N-二甲基乙基)哌嗪基)哌啶基,4-(N-(2-N,N-二乙基乙基)哌嗪基)哌啶基,4-(N-(3-N,N-二甲基丙基)哌嗪基)哌啶基,4-(N-(3-N,N-二乙基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基四氢吡咯基)哌啶基;优选R17选自氢;氢;C1-C6烷基;C3-C7环烷基;-SO2C1-C6烷基;-SO2C2-C6烯基;-COC1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;-COC2-C6烯基,其任选地被卤素、硝基、氨基、氰基取代;更优选R17选自氢;氢;甲基、乙基、异丙基、环丙基;甲磺酰基、乙磺酰基、异丙磺酰基、乙烯基磺酰基;乙酰基、氯乙酰基、溴乙酰基、丙烯酰基、4-N,N-二甲基氨基-2-丁烯酰基,4-四氢吡咯基-2-丁烯酰基;R27选自:1)氢,卤素,硝基,氨基,氰基;2)C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;-O-C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C1-C6含氧烷基;3)甲硫基,乙硫基,异丙硫基,甲亚磺酰基,乙亚磺酰基,异丙亚磺酰基,甲磺酰基,乙磺酰基,异丙磺酰基,氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙氨基磺酰基,羟基甲酰基,甲氧基甲酰基,乙氧基甲酰基,丙氧基甲酰基,异丙氧基甲酰基,正丁氧基甲酰基,异丁氧基甲酰基,叔丁氧基甲酰基,氨基甲酰基,甲胺基甲酰基,乙胺基甲酰基,丙胺基甲酰基,异丙胺基甲酰基,环丙基胺基甲酰基,环丁基胺基甲酰基,环戊基胺基甲酰基,乙酰胺基,丙酰胺基,正丁基酰胺基,异丁基酰胺基,环丙基甲酰胺基,环丁基甲酰胺基,环戊基甲酰胺基,甲磺酰胺基,乙磺酰胺基,丙磺酰胺基,异丙磺酰胺基,二甲基次磷酰基,二乙基次磷酰基,二异丙基次磷酰基;优选R27选自:氢、卤素、硝基、氨基、氰基、C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C3-C7环烷基,其任选地被卤素、硝基、氨基、氰基取代;更优选R27选自:氢、卤素、硝基、氨基、氰基、C1-C6烷基;R37选自:氢;C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C3-C7环烷基,其任选地被卤素、硝基、氨基、氰基取代;优选R37选自:氢;C1-C6烷基;C3-C7环烷基;R47选自:氢;C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C3-C7环烷基,其任选地被卤素、硝基、氨基、氰基取代;优选R47选自:氢;C1-C6烷基;C3-C7环烷基;或上述化合物的立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物;优选药学上可接受的盐为无机酸盐或有机酸盐,其中,所述无机酸盐为盐酸盐、氢溴酸盐、氢碘酸盐、硝酸盐、碳酸氢盐和碳酸盐、硫酸盐或磷酸盐,所述有机酸盐为甲酸盐、乙酸盐、丙酸盐、苯甲酸盐、马来酸盐、富马酸盐、琥珀酸盐、酒石酸盐、柠檬酸盐、抗坏血酸盐、α-酮戊二酸盐、α-甘油磷酸盐、烷基磺酸盐或芳基磺酸盐;优选地,所述烷基磺酸盐为甲基磺酸盐或乙基磺酸盐;所述芳基磺酸盐为苯磺酸盐或对甲苯磺酸盐。
- 根据权利要求1的化合物,其为以下:n8选自0,1或2;优选n8选自0,1;更优选n8为0;R18选自:1)包含选自N、O和S的一个或多个杂原子的五元杂环或六元杂环,所述五元杂环或六元杂环任选地被C1-C6烷基、C1-C6烷氧基、羟基、氨基、C1-C6酰基、氰基、杂环基取代,包括但不限于:4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(N-甲基哌嗪基)哌啶基,4-(N-乙基哌嗪基)哌啶基,4-(N-异丙基哌嗪基)哌啶基,4-(N-乙酰基哌嗪基)哌啶基,4-(N-叔丁氧甲酰基哌嗪基)哌啶基,4-(N-甲磺酰基哌嗪基)哌啶基,4-(N-(2-羟基乙基)哌嗪基)哌啶基,4-(N-(2-氰基乙基)哌嗪基)哌啶基,4-(N-(3-羟基丙基)哌嗪基)哌啶基,4-(N-(2-N,N-二甲基乙基)哌嗪基)哌啶基,4-(N-(2-N,N-二乙基乙基)哌嗪基)哌啶基,4-(N-(3-N,N-二甲基丙基)哌嗪基)哌啶基,4-(N-(3-N,N-二乙基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基四氢吡咯基)哌啶基;2)氨基,环丙基氨基,环丁基氨基,环戊基氨基,环己基氨基,N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基,2-N,N-二甲基氨基乙基氨基,2-羟基乙基氨基,2-吗啡啉基乙基氨基,2-(4-N-甲基哌嗪基)乙基氨基,3-N,N-二甲基氨基丙基氨基,3-N,N-二乙基氨基丙基氨基,3-N,N-二异丙基氨基丙基氨基,3-羟基丙基氨基,3-吗啡啉基丙基氨基,3-(4-N-甲基哌嗪基)丙基氨基,N-甲基哌啶-4-氨基,N-乙基哌啶-4-氨基,N-异丙基哌啶-4-氨基,N-乙酰基哌啶-4-氨基;N-甲基哌嗪基,N-乙基哌嗪基,N-异丙基哌嗪基,N-乙酰基哌嗪基,N-叔丁氧甲酰基哌嗪基,N-甲磺酰基哌嗪基,N-(2-羟基乙基)哌嗪基,N-(2-氰基乙基)哌嗪基,N-(3-羟基丙基)哌嗪基,N-(2-N,N-二甲基乙基)哌嗪基,N-(2-N,N-二乙基乙基)哌嗪基,N-(3-N,N-二甲基丙基)哌嗪基,N-(3-N,N-二乙基丙基)哌嗪基,2-氧代-哌嗪-4-基,N-(N-甲基-4-哌啶基)哌嗪基,N-(N-乙基-4-哌啶基)哌嗪基,N-(N-乙酰基-4-哌啶基)哌嗪基;吗啡啉基,3,5-二甲基吗啡啉基,硫代吗啉基,四氢吡咯基,3-N,N-二甲基四氢吡咯基,3-N,N-二乙基四氢吡咯基;3)C1-C6烷基,其任选地被卤素、硝基、氰基取代;4)C3-C7环烷基,其任选地被卤素、硝基、氰基取代;5)-O-C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;6)-O-C3-C7环烷基,其任选地被卤素、硝基、氨基、氰基取代;7)C6-C10芳基,其任选地被卤素、硝基、氨基、氰基取代;-O-C6-C10芳基,其任选地被卤素、硝基、氨基、氰基取代;8)C2-C6烯基;9)羟基,2-N,N-二甲基氨基乙氧基,2-N,N-二乙基氨基乙氧基,2-N,N-二异丙基氨基乙氧基,2-(N-甲基哌嗪基)乙氧基,2-(N-乙酰基哌嗪基)乙氧基,2-吗啡啉基乙氧基,2-硫代吗啉基乙氧基,2-哌啶基乙氧基,3-N,N-二甲基氨基丙氧基,3-N,N-二乙基氨基丙氧基,3-N,N-二异丙基氨基丙氧基,3-(N-甲基哌嗪基)丙氧基,3-(N-乙酰基哌嗪基)丙氧基,3-吗啡啉基丙氧基,3-硫代吗啉基丙氧基,3-哌啶基丙氧基,2-吡啶基甲氧基,3-吡啶基甲氧基,4-吡啶基甲氧基,苯基甲氧基,单卤素取代苯基甲氧基,偕二卤素取代苯基甲氧基,杂二卤素取代苯基甲氧基;优选R18选自:1)C1-C6烷基,C3-C7环烷基;2)氨基,环丙基氨基,环戊基氨基,环己基氨基,N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基,2-N,N-二甲基氨基乙基氨基,2-羟基乙基氨基,2-吗啡啉基乙基氨基,2-(4-N-甲基哌嗪基)乙基氨基,N-甲基哌啶-4-氨基,N-乙基哌啶-4-氨基,N-异丙基哌啶-4-氨基,N-乙酰基哌啶-4-氨基;3)羟基,2-N,N-二甲基氨基乙氧基,2-N,N-二乙基氨基乙氧基,2-N,N-二异丙基氨基乙氧基,2-(N-甲基哌嗪基)乙氧基,2-(N-乙酰基哌嗪基)乙氧基,2-吗啡啉基乙氧基,2-硫代吗啉基乙氧基,2-哌啶基乙氧基,3-N,N-二甲基氨基丙氧基,3-N,N-二乙基氨基丙氧基,3-N,N-二异丙基氨基丙氧基,3-(N-甲基哌嗪基)丙氧基,3-(N-乙酰基哌嗪基)丙氧基,3-吗啡啉基丙氧基,3-硫代吗啉基丙氧基,3-哌啶基丙氧基,2-吡啶基甲氧基,3-吡啶基甲氧基,4-吡啶基甲氧基;4)哌啶基,4-N,N-二甲基氨基哌啶基,4-羟基哌啶基,4-(N-甲基哌嗪基)哌啶基,4-(N-乙基哌嗪基)哌啶基,4-(N-乙酰基哌嗪基)哌啶基,4-(N-叔丁氧甲酰基哌嗪基)哌啶基,4-(N-甲磺酰基哌嗪基)哌啶基,4-(N-(2-羟基乙基)哌嗪基)哌啶基,4-(N-(2-氰基乙基)哌嗪基)哌啶基,4-(N-(3-羟基丙基)哌嗪基)哌啶基,4-(N-(2-N,N-二甲基乙基)哌嗪基)哌啶基,4-(N-(2-N,N-二乙基乙基)哌嗪基)哌啶基,4-(N-(3-N,N-二甲基丙基)哌嗪基)哌啶基,4-(N-(3-N,N-二乙基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基四氢吡咯基)哌啶基;5)N-甲基哌嗪基,N-乙基哌嗪基,N-异丙基哌嗪基,N-乙酰基哌嗪基,N-(2-羟基乙基)哌嗪基,N-(2-氰基乙基)哌嗪基,N-(3-羟基丙基)哌嗪基,N-(2-N,N-二甲基乙基)哌嗪基,N-(2-N,N-二乙基乙基)哌嗪基,N-(3-N,N-二甲基丙基)哌嗪基,N-(3-N,N-二乙基丙基)哌嗪基,2-氧代-哌嗪-4-基,N-(N-甲基-4-哌啶基)哌嗪基,N-(N-乙基-4-哌啶基)哌嗪基,N-(N-乙酰基-4-哌啶基)哌嗪基;6)吗啡啉基,3,5-二甲基吗啡啉基,硫代吗啉基,四氢吡咯基,3-N,N-二甲基四氢吡咯基,3-N,N-二乙基四氢吡咯基;更优选R18选自:1)甲基,乙基,异丙基,三氟甲基;2)氨基,环丙基氨基,N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基;3)羟基;4)哌啶基,4-N,N-二甲基氨基哌啶基,4-羟基哌啶基,4-(N-甲基哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基四氢吡咯基)哌啶基;5)N-甲基哌嗪基,N-乙基哌嗪基,N-异丙基哌嗪基,N-乙酰基哌嗪基,N-(2-羟基乙基) 哌嗪基,N-(2-氰基乙基)哌嗪基,N-(3-羟基丙基)哌嗪基,N-(2-N,N-二甲基乙基)哌嗪基,N-(2-N,N-二乙基乙基)哌嗪基,N-(3-N,N-二甲基丙基)哌嗪基,N-(3-N,N-二乙基丙基)哌嗪基,2-氧代-哌嗪-4-基,N-(N-甲基-4-哌啶基)哌嗪基,N-(N-乙基-4-哌啶基)哌嗪基,N-(N-乙酰基-4-哌啶基)哌嗪基;6)吗啡啉基,3,5-二甲基吗啡啉基,硫代吗啉基,四氢吡咯基,3-N,N-二甲基四氢吡咯基,3-N,N-二乙基四氢吡咯基;R28选自:1)氢,卤素,硝基,氨基,氰基;2)C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;-O-C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C1-C6含氧烷基;3)甲硫基,乙硫基,异丙硫基,甲亚磺酰基,乙亚磺酰基,异丙亚磺酰基,甲磺酰基,乙磺酰基,异丙磺酰基,氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙氨基磺酰基,羟基甲酰基,甲氧基甲酰基,乙氧基甲酰基,丙氧基甲酰基,异丙氧基甲酰基,正丁氧基甲酰基,异丁氧基甲酰基,叔丁氧基甲酰基,氨基甲酰基,甲胺基甲酰基,乙胺基甲酰基,丙胺基甲酰基,异丙胺基甲酰基,环丙基胺基甲酰基,环丁基胺基甲酰基,环戊基胺基甲酰基,乙酰胺基,丙酰胺基,正丁基酰胺基,异丁基酰胺基,环丙基甲酰胺基,环丁基甲酰胺基,环戊基甲酰胺基,甲磺酰胺基,乙磺酰胺基,丙磺酰胺基,异丙磺酰胺基,二甲基次磷酰基,二乙基次磷酰基,二异丙基次磷酰基;优选R28选自:氢、卤素、硝基、氨基、氰基、C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C3-C7环烷基,其任选地被卤素、硝基、氨基、氰基取代;更优选R28选自:氢、卤素、硝基、氨基、氰基、C1-C6烷基;R38选自:氢;C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C3-C7环烷基,其任选地被卤素、硝基、氨基、氰基取代;优选R38选自:氢;C1-C6烷基;C3-C7环烷基;R48选自:氢;C1-C6烷基,其任选地被卤素、硝基、氨基、氰基取代;C3-C7环烷基,其任选地被卤素、硝基、氨基、氰基取代;优选R48选自:氢;C1-C6烷基;C3-C7环烷基;或上述化合物的立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物;优选药学上可接受的盐为无机酸盐或有机酸盐,其中,所述无机酸盐为盐酸盐、氢溴酸盐、氢碘酸盐、硝酸盐、碳酸氢盐和碳酸盐、硫酸盐或磷酸盐,所述有机酸盐为甲酸盐、乙酸盐、丙酸盐、苯甲酸盐、马来酸盐、富马酸盐、琥珀酸盐、酒石酸盐、柠檬酸盐、抗坏血酸盐、α-酮戊二酸盐、α-甘油磷酸盐、烷基磺酸盐或芳基磺酸盐;优选地,所述烷基磺酸盐为甲基磺酸盐或乙基磺酸盐;所述芳基磺酸盐为苯磺酸盐或对甲苯磺酸盐。
- 制备权利要求1所述的化合物的方法,在以下合成方法中,在式R41Z、R31Z符号Z表示离去基团,如卤素、甲磺酸根、三氟甲磺酸根反应条件:(a)碱性条件(如二异丙基乙基胺,三乙胺,碳酸钾等)的取代反应;(b)硝基还原反应(如铁粉/醋酸等);(c)碱性条件的酯水解反应(如氢氧化锂等);(d)酰胺缩合环化(如2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯等缩合试剂);(e)碱性条件(如钠氢等);(f)酸性条件(三氟乙酸,盐酸等)或钯催化的胺化反应;或反应条件:(a)碱性条件(如二异丙基乙基胺,三乙胺,碳酸钾等)的取代反应;(b)硝基还原反应(如铁粉/醋酸等);(c)碱性条件的酯水解反应(如氢氧化锂等);(d)酰胺缩合环化(如2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯等缩合试剂);(e)碱性条件(如钠氢等);(f)酸性条件(三氟乙酸,盐酸等)或钯催化的胺化反应。
- 药物组合物,其包含权利要求1-7中任一项的化合物或其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物以及任选的药学上可以接受的赋形剂。
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/077,634 US10975092B2 (en) | 2016-03-04 | 2017-03-02 | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof |
AU2017226499A AU2017226499B2 (en) | 2016-03-04 | 2017-03-02 | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof |
KR1020187023885A KR20180114057A (ko) | 2016-03-04 | 2017-03-02 | 피리미딘 7-원 고리 화합물, 이의 제조 방법, 이의 약제학적 조성물, 및 이의 용도 |
CA3012516A CA3012516A1 (en) | 2016-03-04 | 2017-03-02 | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition therefor, and uses thereof |
NZ744393A NZ744393B2 (en) | 2016-03-04 | 2017-03-02 | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof |
JP2018535176A JP2019512459A (ja) | 2016-03-04 | 2017-03-02 | 7員環化合物、その調製方法、その医薬組成物、およびその使用 |
MX2018009189A MX2018009189A (es) | 2016-03-04 | 2017-03-02 | Compuestos de anillo de siete miembros de pirimidina. |
RU2018124591A RU2748696C2 (ru) | 2016-03-04 | 2017-03-02 | Пиридиновые соединения, содержащие семь атомов в кольце, способ их получения, фармацевтическая композиция, содержащая указанные соединения, и их применение |
EP17759257.3A EP3424929A4 (en) | 2016-03-04 | 2017-03-02 | PYRIMIDINE CYCLIC COMPOUNDS WITH SEVEN MEMBERS, PREPARATION METHOD THEREFOR, RELATED PHARMACEUTICAL COMPOSITION AND USES THEREFOR |
ZA2018/05600A ZA201805600B (en) | 2016-03-04 | 2018-08-22 | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610121108.5 | 2016-03-04 | ||
CN201610121108 | 2016-03-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017148406A1 true WO2017148406A1 (zh) | 2017-09-08 |
Family
ID=59743511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/075416 WO2017148406A1 (zh) | 2016-03-04 | 2017-03-02 | 嘧啶类七元环化合物、其制备方法、药用组合物及其应用 |
Country Status (13)
Country | Link |
---|---|
US (1) | US10975092B2 (zh) |
EP (1) | EP3424929A4 (zh) |
JP (1) | JP2019512459A (zh) |
KR (1) | KR20180114057A (zh) |
CN (1) | CN107151250B (zh) |
AU (1) | AU2017226499B2 (zh) |
CA (1) | CA3012516A1 (zh) |
HK (1) | HK1249499A1 (zh) |
MX (1) | MX2018009189A (zh) |
RU (1) | RU2748696C2 (zh) |
TW (1) | TWI748996B (zh) |
WO (1) | WO2017148406A1 (zh) |
ZA (1) | ZA201805600B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3440084A4 (en) * | 2016-04-07 | 2019-11-20 | Dana-Farber Cancer Institute, Inc. | KINASE SCAFFOLDING PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS FOR TREATING PI3K-INDUCED DISORDERS |
WO2020231726A1 (en) * | 2019-05-10 | 2020-11-19 | Dana-Farber Cancer Institute, Inc. | Small-molecule focal adhesion kinase (fak) inhibitors |
WO2021024141A1 (en) * | 2019-08-08 | 2021-02-11 | Xiaoxiang Li | Prevention or treatment of diseases and disorders associated with tissue damage |
AU2017346845B2 (en) * | 2016-10-18 | 2021-12-02 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111039944B (zh) * | 2018-10-12 | 2021-11-23 | 中国科学院合肥物质科学研究院 | Mst1激酶抑制剂及其用途 |
CN113717941B (zh) * | 2020-05-26 | 2023-11-14 | 中科院合肥技术创新工程院 | 一种用于喉癌上皮细胞的培养基、培养方法及其应用 |
KR102498531B1 (ko) * | 2020-06-29 | 2023-02-13 | 한국과학기술연구원 | 단백질 카이네이즈 trkc에 선택적인 억제제로서의 신규 피리미도디아제핀 유도체 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080242608A1 (en) | 2006-06-02 | 2008-10-02 | Azad Bonni | Methods and compositions for treating and preventing neurologic disorders |
WO2010080712A2 (en) * | 2009-01-06 | 2010-07-15 | Dana Farber Cancer Institute | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
WO2014145909A2 (en) * | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone compounds and methods of treating disorders |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006089298A2 (en) * | 2005-02-18 | 2006-08-24 | Attenuon, Llc | Pyrimidine-fused diazepine derivatives and indole-fused pteridines |
PL2205603T3 (pl) * | 2007-09-28 | 2014-07-31 | Cyclacel Ltd | Pochodne pirymidyny jako inhibitory kinaz białkowych |
WO2015117087A1 (en) * | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
-
2017
- 2017-03-02 TW TW106106791A patent/TWI748996B/zh not_active IP Right Cessation
- 2017-03-02 AU AU2017226499A patent/AU2017226499B2/en not_active Ceased
- 2017-03-02 WO PCT/CN2017/075416 patent/WO2017148406A1/zh active Application Filing
- 2017-03-02 KR KR1020187023885A patent/KR20180114057A/ko active IP Right Grant
- 2017-03-02 RU RU2018124591A patent/RU2748696C2/ru active
- 2017-03-02 EP EP17759257.3A patent/EP3424929A4/en not_active Withdrawn
- 2017-03-02 JP JP2018535176A patent/JP2019512459A/ja active Pending
- 2017-03-02 US US16/077,634 patent/US10975092B2/en active Active
- 2017-03-02 CA CA3012516A patent/CA3012516A1/en not_active Abandoned
- 2017-03-02 CN CN201710118734.3A patent/CN107151250B/zh active Active
- 2017-03-02 MX MX2018009189A patent/MX2018009189A/es unknown
-
2018
- 2018-03-07 HK HK18103236.8A patent/HK1249499A1/zh unknown
- 2018-08-22 ZA ZA2018/05600A patent/ZA201805600B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080242608A1 (en) | 2006-06-02 | 2008-10-02 | Azad Bonni | Methods and compositions for treating and preventing neurologic disorders |
WO2010080712A2 (en) * | 2009-01-06 | 2010-07-15 | Dana Farber Cancer Institute | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
WO2014145909A2 (en) * | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone compounds and methods of treating disorders |
Non-Patent Citations (12)
Title |
---|
"Burger's Medicinal Chemistry and Drug Discovery", vol. 172-178, 1995, pages: 949 - 982 |
"Cancer Cell", vol. 16, 2009, pages: 425 - 438 |
"Purification Reagent Reference Purification of Laboratory Chemicals", 1980, PERGAMON PRESS |
"Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING COMPANY |
CANCER CELL, vol. 16, 2009, pages 425 - 438 |
CELL BIOSCI, vol. 3, 2013, pages 34 |
CELL, vol. 125, 2006, pages 987 - 1001 |
J.EXP.MED., vol. 209, 2012, pages 741 - 759 |
NAT CELL BIOL., vol. 13, no. 8, 2011, pages 877 - 83 |
NAT. REV. CANCER, vol. 9, 2009, pages 28 - 39 |
SCIENCE, vol. 298, 2002, pages 1912 - 1934 |
See also references of EP3424929A4 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3440084A4 (en) * | 2016-04-07 | 2019-11-20 | Dana-Farber Cancer Institute, Inc. | KINASE SCAFFOLDING PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS FOR TREATING PI3K-INDUCED DISORDERS |
US11155556B2 (en) | 2016-04-07 | 2021-10-26 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders |
AU2017346845B2 (en) * | 2016-10-18 | 2021-12-02 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders |
WO2020231726A1 (en) * | 2019-05-10 | 2020-11-19 | Dana-Farber Cancer Institute, Inc. | Small-molecule focal adhesion kinase (fak) inhibitors |
WO2021024141A1 (en) * | 2019-08-08 | 2021-02-11 | Xiaoxiang Li | Prevention or treatment of diseases and disorders associated with tissue damage |
CN114728009A (zh) * | 2019-08-08 | 2022-07-08 | 李晓祥 | 预防或治疗与组织损伤相关的疾病和紊乱 |
Also Published As
Publication number | Publication date |
---|---|
ZA201805600B (en) | 2023-02-22 |
RU2018124591A3 (zh) | 2020-07-24 |
CN107151250B (zh) | 2020-03-27 |
CA3012516A1 (en) | 2017-09-08 |
RU2018124591A (ru) | 2020-04-06 |
HK1249499A1 (zh) | 2018-11-02 |
AU2017226499A1 (en) | 2018-09-20 |
RU2748696C2 (ru) | 2021-05-28 |
US20200115386A1 (en) | 2020-04-16 |
JP2019512459A (ja) | 2019-05-16 |
EP3424929A1 (en) | 2019-01-09 |
CN107151250A (zh) | 2017-09-12 |
AU2017226499B2 (en) | 2020-10-22 |
KR20180114057A (ko) | 2018-10-17 |
TW201731850A (zh) | 2017-09-16 |
EP3424929A4 (en) | 2019-08-07 |
TWI748996B (zh) | 2021-12-11 |
MX2018009189A (es) | 2018-11-09 |
NZ744393A (en) | 2021-09-24 |
US10975092B2 (en) | 2021-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017148406A1 (zh) | 嘧啶类七元环化合物、其制备方法、药用组合物及其应用 | |
JP7050093B2 (ja) | 置換5員および6員複素環式化合物、その調製方法、薬剤の組み合わせおよびその使用 | |
JP7145873B2 (ja) | 5員環および6員環が縮合したアザ環式芳香族系化合物、その製造方法、医薬組成物およびその応用 | |
CN109983007A (zh) | 酰胺类衍生物抑制剂及其制备方法和应用 | |
CN105849099A (zh) | 周期蛋白依赖性激酶7(cdk7)的多环抑制剂 | |
CN107849050B (zh) | 化合物 | |
JP2020189852A (ja) | キナーゼ阻害活性を有するベンズヒドロール−ピラゾール誘導体及びその使用 | |
CA3003554C (en) | Pyrropyrimidine compounds as mnks inhibitors | |
WO2019001556A1 (zh) | 取代芳基醚类化合物、其制备方法、药用组合物及其应用 | |
CN110914253B (zh) | 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途 | |
TW202033520A (zh) | 用作fgfr4抑制劑的稠環衍生物 | |
KR20200112810A (ko) | 헤테로아릴 아미드 화합물, 이에 대한 제조 방법, 이의 약학적 조성물 및 이의 적용 | |
CN115466289A (zh) | 具有tyk2抑制活性的化合物,包含其的药物组合物,及其应用 | |
WO2021249324A1 (zh) | 烯基嘧啶类化合物、其制备方法与应用 | |
TWI807343B (zh) | 取代喹唑啉類化合物、藥物組合物及應用 | |
NZ744393B2 (en) | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof | |
WO2021254464A1 (zh) | 取代喹唑啉类化合物、其制备方法、药物组合及应用 | |
JP6927959B2 (ja) | ベンジリデングアニジン誘導体と化学療法剤の併用による癌の治療方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2018535176 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3012516 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2018/009189 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017226499 Country of ref document: AU Date of ref document: 20170302 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017759257 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017759257 Country of ref document: EP Effective date: 20181004 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17759257 Country of ref document: EP Kind code of ref document: A1 |